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Abstract of Dissertation 
 
 
 
 
STUDIES OF THE EFFECTS OF DOPAMINE NEURON STIMULATING 
PEPTIDES IN RODENT MODELS OF NORMAL AND DYSFUNCTIONAL 
DOPAMINERGIC SYSTEMS 
 
A theoretical post-translational processing model of the proprotein form of 
glial cell line-derived neurotrophic factor (GDNF) likely produces three 
biologically active peptides. The three prospective peptides formed are 5, 11, and 
17 amino acid peptides, entitled dopamine neuron stimulating peptide -5 (DNSP-
5), -11 (DNSP-11), and -17 (DNSP-17), respectively. The DNSPs were 
hypothesized to increase dopaminergic neuron function because of their 
relationship to GDNF: a molecule with established neurotrophic actions on 
dopaminergic neurons. The DNSPs have the potential to provide a therapeutic 
molecule similar to GDNF, but with increased ease of delivery and improved 
bioavailability. 
Neurochemical effects of DNSPs were examined in the nigrostriatal 
pathway of normal Fischer 344 rats, and DNSP-11 was found to be the most 
effective in increasing dopamine neurochemical function. Striatal microdialysis, 
four weeks after a single intranigral administration of DNSP-11, showed 
significant increases in the baseline concentrations of dopamine, DOPAC, and 
HVA. In addition, both, potassium and d-amphetamine-evoked dopamine 
overflow were significantly increased.  
DNSP-11 was delivered intranigrally to aged Fischer 344 rats to examine 
DNSP-11’s ability to improve dopaminergic function in aged dopamine neurons. 
DNSP-11 affected striatal dopaminergic function 28 days after treatment by 
decreasing baseline concentrations of dopamine and evoked dopamine release.  
Investigation of DNSP-11 continued, using two models of neurotoxin-
induced dopamine neuron loss that model cell loss associated with Parkinson’s 
disease. The neuroprotective properties of DNSP-11 were evaluated by 
delivering DNSP-11 prior to the neurotoxic insult. DNSP-11 treatment was unable 
to protect dopaminergic neurons, but significantly increased dopamine 
metabolism. In a model of severe dopamine neuron loss, DNSP-11 treatment 
significantly improved apomorphine-induced rotation behavior, indicative of 
alterations in the function of nigrostriatal dopaminergic neurons. Subsequent 
 
examination of dopamine content within the SN revealed significant increases in 
dopamine and DOPAC levels by DNSP-11. 
Taken together, DNSP-11 treatments modified dopamine neurochemistry 
in all investigated rodent models. The observed long-term alterations of 
dopamine neurochemistry by DNSP-11 and subsequent behavioral changes 
support a potential use for DNSP-11 as a therapeutic for dopaminergic cell loss. 
Increased dopaminergic function by DNSP-11 is evidence for the novel concept 
that peptides contained within the prodomain of trophic factors can have 
neurotrophic actions.  
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Chapter One: Introduction 
Overview 
Parkinson’s disease (PD) is a neurodegenerative disease characterized 
by the progressive loss and dysfunction of dopaminergic neurons. Increasingly 
debilitating motor disturbances are associated with the disruption of 
dopaminergic neurons (Wichmann and DeLong, 2006). Currently, clinical 
therapies for PD focus on increasing the concentration of the lost 
neurotransmitter, dopamine. Over time, neurotransmitter replacement therapies 
become less effective at managing the motor disruptions associated with PD 
because they fail to stop or reverse the neuronal loss (Goudreau, 2006). A 
neurotrophic factor, glial cell-line derived neurotrophic factor (GDNF), has 
previously shown the ability to restore and enhance the function of dopaminergic 
neurons (Hoffer et al., 1994; Gash et al., 1996; Hebert et al., 1996; Slevin et al., 
2005). GDNF combats the underlying neuronal dysfunction associated with PD, 
but difficulties with delivery and potential toxic effects halted ongoing clinical 
trials.  
An effort was made to identify a molecule with similar functional effects as 
GDNF with greater ease of administration and bioavalability. Therefore, a post-
translational processing model of the proprotein form of GDNF was developed 
that may produce three bioactive peptides (Glass, 2004). The three peptides, 
known as dopamine neuron stimulating peptides (DNSPs), should have improved 
bioavailability and be more readily synthesized and modified than their parent 
molecule, GDNF. However, investigation of their functional impact on 
dopaminergic neurons still needed to be examined in vivo. Rodent models were 
used to test DNSPs’ functional effects on dopaminergic neurons, focusing on the 
nigrostriatal pathway. Within this dissertation: I established the DNSPs ability to 
modify dopaminergic function, identified the DNSP most effective at altering 
dopaminergic function, and provided evidence for the DNSPs’ ability to improve 
dopamine neuron function in dysfunctional dopaminergic systems. The goal of 
this dissertation is to aid in the development of a therapeutic molecule that can 
stop or reverse the dopaminergic neuron loss and dysfunction associated with 
2 
PD. Therefore, results achieved with the DNSPs were compared to previous 
results with GDNF because the neurotrophic actions of GDNF on dopaminergic 
neurons are considered the “gold standard” (Peterson and Nutt, 2008). 
Dopamine: A Brief History 
Dopamine (DA) was first synthesized in 1910, but 40 years passed before 
it was discovered in mammalian tissue and almost another 10 years before it was 
accepted as a neurotransmitter. DA, or 3-hydroxytyramine, is a catecholamine 
derived from the amino acid tyrosine and was discovered in the sheep heart and 
adrenal medulla (Goodall, 1951). At the time DA was discovered, in mammalian 
tissue, it was theorized to function primarily as an intermediate in the production 
of the neurotransmitters, epinephrine, and norepinephrine (NE) (Blaschko, 1942). 
But by the late 1950’s, Carlsson and others began to demonstrate that the 
dopamine precursor L-3,4-dihyroxyphenylalanine (L-dopa) alleviated catalepsy 
related to reserpine, a vesicular monoamine transporter (VMAT)  blocker 
(Carlsson et al., 1957). The activity of L-dopa renewed interest in DA, and shortly 
afterward, DA was discovered in the mammalian brain (Montagu, 1957). Two 
years later in 1959 the distribution of DA was characterized in the CNS of 
humans and determined to be concentrated in extrapyramidal neurons (Sano et 
al., 1959). Hornykiewicz expanded upon studies of DA in the human CNS and 
provided the first evidence of DA depletion in the striatum and substantia nigra 
(SN) in Parkinson’s disease (Ehringer and Hornykiewicz, 1960; Hornykiewicz, 
1963). Since these discoveries, PD has been characterized by the loss of DA in 
the nigrostriatal pathway. By 1969, the combinatorial PD therapeutic L-dopa and 
carbidopa, a peripheral dopa decarboxylase inhibitor, began use as the primary 
treatment for PD. Neurotransmitter replacement therapy became widely accepted 
and L-dopa / carbidopa is the most commonly used today, now known as 
Sinemet ®. 
Dopamine Systems 
Knowledge of the function and regulation of DA in the CNS has been 
continually advanced since its discovery in 1951 and will be discussed 
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throughout this chapter. There are four primary dopaminergic systems in the 
CNS: mesocortical, mesolimbic, tuberoinfundibular, and nigrostriatal (Cooper et 
al., 2003). The tuberoinfundibular system is part of the neuroendocrine regulation 
of the release of prolactin from the anterior pituitary gland. Hormone regulation is 
a distinct function of the tuberoinfundibular system relative to other dopaminergic 
systems and necessitates only short to intermediate length dopaminergic 
projections (Björklund et al., 2005). The mesocortical dopaminergic system is the 
primary dopaminergic input to the prefrontal cortex from the midbrain nuclei, 
specifically the ventral tegmental area (VTA) and SN. Evidence supports that the 
mesocortical system is involved in higher cognitive functions such as attention 
direction, stimulus prioritization, and “working memory.” Dysfunctions within the 
mesocortical dopaminergic projections are potentially related to the cognitive 
deficits observed in schizophrenia and attention deficit hyperactivity disorder 
(ADHD) (Iversen, 2009). Mesolimbic and mesocortical systems have similar 
originating nuclei in the VTA and SN but the mesolimbic system projects to more 
posterior structures such as the nucleus accumbens and amygdala. The 
mesolimbic system has been implicated in motivation and reward with emphasis 
on a role in drug abuse and other addictive behaviors (Iversen, 2009). The 
nigrostriatal system at its most basic level is considered to be the dopaminergic 
projections from the SN that travel through the medial forebrain bundle (mfb) to 
the striatum, but projections from the VTA to the striatum travel in the same fiber 
bundle and project to similar areas with overlapping activity (Borrelli and Di 
Chiara, 2002). 
 Dopaminergic neuron function is involved in multiple aspects of behavior 
and cognition, and the projections from the three long dopaminergic systems, 
mesolimbic, mesocortical, and nigrostriatal, overlap providing some functional 
redundancy between the systems. The nigrostriatal system is involved in the 
motor deficits associated with PD and therefore is the system of primary interest 
in this dissertation. 
 
 
4 
Striatum  
Striatum is a term that includes the caudate nucleus and putamen, which 
in primates are distinct structures separated by the internal capsule. In the rat, 
the caudate nucleus and putamen are indistinguishable because the sparsely 
organized internal capsule provides no structural division. The resulting structure 
is a combination of the caudate nucleus and putamen striated with white matter 
fiber tracts and therefore, labeled the striatum (Mueller et al., 1989). In the rat, 
the striatum is subdivided into the dorsal and ventral areas based on the 
innervating fibers and the divergence of function. The DA afferents to the dorsal 
striatum classically are considered to be from the SN with primary involvement in 
motor movement. The ventral striatum includes the nucleus accumbens and 
olfactory tubercule. The primary dopaminergic input to the ventral striatum arises 
from the VTA and is involved in reward behavior (van Domburg and ten 
Donkelaar, 1991).  
The striatum primarily consists of medium spiny neurons (~95 %) with 
GABAergic efferents divided between the SN reticulata (SNr) and internal 
segment of the globus pallidus (GPi) or external segment of the globus pallidus 
(GPe) (Figure 1.1). Within the striatum interneuronal connections are made by 
large aspiny acetylcholinergic neurons and medium aspiny GABAergic neurons 
(Nicola et al., 2000). Both interneuronal populations interact with the medium 
spiny neurons, but they also receive input from striatal afferents (Smith and 
Kieval, 2000). The striatum is innervated and modulated by dopaminergic 
neurons of the SN and glutamatergic neurons from the cortex and thalamus 
(Tepper et al., 2007). The glutamatergic and dopaminergic striatal afferents form 
synapses with interneuron types as well as medium spiny neurons. The 
dopaminergic afferents, in particular, innervate the acetylcholinergic interneurons 
and the glutamatergic afferents innervate the GABAergic interneurons with some 
overlap (Di Chiara et al., 1994). The DA input from the SN directly alters 
interneuron and efferent neuron function of the striatum providing strong 
modulatory control over the GABAergic efferents of the striatum.  
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The neuronal populations within the striatum are compartmentalized by 
specific afferent and efferent neurons into two areas divided 
immunohistochemically by the absence or presence of acetylcholinesterase 
(Graybiel and Ragsdale, 1978). The two distinct areas within the striatum have 
been termed the patch or the matrix. The patch, initially termed the striosome, 
lacks acetylcholinesterase and therefore maintains a high concentration of 
acetylcholine and is primarily innervated by limbic associated areas such as the 
hippocampus. The matrix, initially termed the extrastriosomal matrix, has a high 
concentration of acetylcholinesterase maintaining a choline rich environment and 
is the primary innervation area for cortical and thalamic glutamatergic projections 
(Gerfen, 1992). The DA projections from the SN primarily innervate the patch 
areas, which are most concentrated in the dorsolateral striatum and decline in a 
graded manner moving ventromedially within the striatum (Björklund et al., 2005). 
With the study of the compartmentalization of the striatum and mapping of 
cortical projections, there has been a shift in the division of the striatum (Gerfen, 
1992). The striatum is now divided into three primary divisions: the limbic, 
associative, and motor. The limbic area is the ventral portion of the striatum and 
the motor area consists of the dorsolateral striatum. The new division of the 
striatum, the associative area, is in the central striatum between the limbic and 
motor areas (Borrelli and Di Chiara, 2002). The significance of this division of the 
striatum is that the midbrain projections follow a similar layout with the medial 
VTA projecting to the ventral striatum with few patch compartments and the 
lateral SN projecting to the dorsolateral striatum with a large number of patch 
compartments. The limbic area in the central striatum is a mixture of VTA and SN 
projections and contains a mixture of matrix and patch compartments (Joel and 
Weiner, 2000). The large degree of heterogeneity exhibited by midbrain DA 
innervations provides sampling from both the VTA and SN to varying degrees 
within all areas of the striatum. The heterogeneity of the striatum and multiple 
afferent and efferent fibers adds complexity to a study, but the SN projections to 
the striatum and subsequent motor area are well defined and can be targeted for 
study.  
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The primary DA innervation to the motor areas in the striatum arises in the 
SNc forming the nigrostriatal pathway. The dopaminergic projections target the 
patch areas in the dorsolateral striatum and modulate motor movement by 
innervating striatal interneurons and afferent fibers to the globus pallidus and the 
SNr. Therefore, the SN as a whole provides striatal efferents and receives 
afferent projections from the striatum, making it critical in the modulation of motor 
movement. 
Substantia Nigra  
As discussed above, the SN is divided into two distinct areas, the SNc and 
SNr. The SNc is a densely packed band of cell bodies containing approximately 
44% of the cell bodies in the SN (Poirier et al., 1983). The SNr is ventral to the 
SNc and is sparsely populated with neuronal cell bodies. The SNr does maintain 
a dense innervation of GABAergic projections from the striatum and 
glutamatergic innervation from  the subthalamic nucleus (STN) (Tepper et al., 
2007). The SNr also receives dopaminergic input from a small population of SNc 
cell bodies that send fingerlike dendritic arborizations into the neighboring 
reticulata (Smith and Kieval, 2000). The SNr’s GABAergic axonal projections 
primarily innervate the thalamus but also interact with the SNc altering 
dopaminergic release and activation. The SNc is the primary area containing 
dopaminergic neurons within the SN, and in addition to connections to the SNr, 
the SNc has axonal projections to the striatum, cortex, and amygdala (Loughlin 
and Fallon, 1983, 1984). Most of the dopaminergic output of the SN is directed to 
the striatum but the dopaminergic neurons are modulated through GABAergic 
input from the SNr and feedback from the striatum. The loss of dopaminergic 
neurons in the SN disrupts the function of multiple systems and in the basal 
ganglia circuitry, GABAergic fibers are released from the regulatory effects of DA, 
negatively modulating related motor movement. 
The Basal Ganglia: Direct and Indirect Pathways 
The nigrostriatal pathway is involved in the modulation and initiation of 
motor movement but does not project directly to the cortical motor centers. The 
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influence of the nigrostriatal pathway on motor movement is related to the 
downstream effects of striatal projections on the thalamus, which directly 
influences cortical motor output (Figure 1.1). The nigrostriatal dopaminergic  
projections can modulate the thalamocortical input through two pathways, the 
direct pathway and indirect pathway (Blandini et al., 2000). Both pathways 
originate in the nigrostriatal dopaminergic projections and differentiate through 
the DA receptor subtypes on their innervating post-synaptic striatal neuron. The 
direct pathway signals primarily through the D1 family of DA receptors, a 
stimulatory receptor discussed later within this chapter. The indirect pathway 
signals primarily through the D2 family of DA receptors, an inhibitory receptor 
discussed later within this chapter. The activated post-synaptic neurons of the 
direct pathway in the striatum innervate the GPi, which directly regulates the 
thalamocortical projections through GABAergic inhibitory effects (Nicola et al., 
2000; Björklund et al., 2005). The inhibited post-synaptic neurons of the indirect 
pathway innervate the subthalamic nucleus (STN) and this inhibits the excitatory 
output from the STN on the GPi (Tepper et al., 2007).  
A hallmark of PD is the loss of the dopaminergic input into the striatum 
from the SN and with the loss, a lack of activation occurs in the direct pathway 
and subsequent release of the GPi from inhibition. The loss of DA input in the 
indirect pathway disinhibits the STN increasing the activation of the GPi. The GPi 
released from direct pathway inhibition and stimulated by the indirect pathway 
causes increased inhibition of thalamocortical projections and thereby reduces 
the glutamatergic input to the cortices from the thalamus (Blandini et al., 2000). 
The reduction in cortical glutamate signaling manifests behaviorally through 
hypokinesia (DeLong and Wichmann, 2007).  
The simplified model system of the cortico-basal ganglia-cortical circuit 
has recently been under scrutiny for its lack of encompassing all basal ganglia 
inputs and interconnections and when modeling the dysfunctional systems of PD 
it does not encompass all affected areas (Braak et al., 2004). For review of a 
more complete model of the basal ganglia interactions including spinal cord and 
neocortical motor centers please refer to Braak and Del Tredici, 2008. The author 
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Figure 1.1 The Direct and Indirect Pathways of the Basal Ganglia 
A simplified model of the basal ganglia demonstrating the divergence of the 
direct and indirect pathways within the striatum adapted from Blandini, 2000. The 
direct and indirect pathways diverge within the striatum through SN DA signaling 
on two distinct groups of receptors, D1 and D2. The D1 receptors provide a 
stimulatory signal on the post-synaptic neuron and the D2 receptor provides an 
inhibitory signal on the post-synaptic neuron. The expression of the receptors 
localizes them to the neurons projecting through the subsequent pathways. This 
model of basal ganglia function does not exhibit the complex interconnections of 
the basal ganglia and other motor centers, but demonstrates the involvement of 
the nigrostriatal pathway in motor output.  
+ post-synaptic stimulatory effects and – post-synaptic inhibitory effects  
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concedes the model system of the direct and indirect pathways described above 
is not complete, but the connection between the SN and motor output is apparent 
using this model and demonstrates the necessity of studying the nigrostriatal 
pathway related to movement dysfunction. 
Dopamine Synthesis, Release, Uptake, and Metabolism 
DA, the primary neurotransmitter of the nigrostriatal pathway, is 
synthesized from tyrosine to DA through a two-step synthesis (Figure 1.2). 
Tyrosine is a naturally occurring non-essential amino acid that can be 
synthesized from phenylalanine. Tyrosine is converted to L-dopa through an 
enzymatic reaction with tyrosine hydroxylase (TH) and the co-factors 
tetrahydrobiopterin and Fe2+. The production of L-dopa by TH is the rate-limiting 
step in DA production (Carlsson et al., 1972; Haavik and Toska, 1998). L-dopa is 
converted to DA by L-aromatic amino acid decarboxylase (L-AADC), which is 
regulated by protein production. TH activity is regulated by the phosphorylation of 
4 serine residues enhancing its affinity for the cofactor tetrahydrobiopterin 
(Kumer and Vrana, 1996). Synthesized DA is packaged into vesicles by the 
vesicular monoamine transporter 2 where it remains until a release event. 
Modulation of TH function and the synthesis of DA alter available DA for release 
and the functional signaling of dopaminergic neurons. 
DA release is initiated by an action potential that depolarizes the 
membrane potential and allows calcium influx through voltage-gated calcium 
channels. Calcium interacts with vesicles and initiates vesicle docking and 
release of DA (Figure 1.3). DA release into the synaptic cleft binds to post 
synaptic receptors or presynaptic autoreceptors. There are five isoforms of the 
post-synaptic DA receptor divided between two families. DA receptors of both 
families are G protein coupled receptors that modulate protein kinase A (PKA) 
through the stimulation or inhibition of adenylate cyclase. The D1 family of 
receptors activates adenylate cyclase and the D2 family of receptors down 
regulates adenylate cyclase (Wooten, 1997). The modulation of PKA by 
adenylate cyclase directly modifies the activity of DARPP-32 (Dopamine and 
cAMP regulated phosphoprotein of 32 kDa). 
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Figure 1.2 Dopamine Synthesis 
L-Tyrosine is converted to L-dopa by TH and undergoes conversion to DA by L-
AADC. The dopamine molecule is then packaged into vesicles through the 
vesicular monoamine transporter. The packaged dopamine is ready to be 
released into the synapse. 
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Figure 1.3 Dopamine Receptor Interactions 
DA signals post-synaptically through D1 and D2 family receptors. Both receptor 
types are G protein coupled and modulate adenylate cyclase. D1 like receptors 
activate adenylate cyclase and D2 like receptors inhibit adenylate cyclase. DA 
signals presynaptically through D2 / D3 like autoreceptors modulating DA 
synthesis, release, and firing rate. 
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Activated DARPP-32 inhibits the activity of Protein Phosphatase-1 (PP-1) 
(Hemmings et al., 1984; Hemmings et al., 1989). Therefore, D1 like receptors 
stimulate adenylate cyclase increasing DARPP-32 activity and inhibit PP-1. 
Whereas, D2-like receptors inhibit adenylate cyclase thereby decreasing DARPP-
32 activity and increasing the activity of PP-1 (Nishi et al., 1999). DA receptor 
activation modulates ion influxes and protein activity (Ouimet et al., 1988; 
Surmeier et al., 1995). The modification of protein activity can modify receptor or 
channel expression and function leading to alterations in synaptic plasticity. The 
two different receptor families lead to the ability of DA signaling to provide 
inhibitory or stimulatory effects based on which post-synaptic receptor is 
activated (Lindskog et al., 1999)  
Presynaptic receptors on dopaminergic neurons are considered 
autoreceptors and fall into the D2 / D3 family of receptors (Feuerstein, 2008). DA 
autoreceptors primarily regulate three areas of DA signaling: synthesis, release, 
and firing rate. The regulation of synthesis and release is performed by 
autoreceptors located on the axon terminal and firing rate is regulated by 
autoreceptors on the soma or dendrites (Lindgren et al., 2001). DA autoreceptors 
provide a mechanism for DA to self regulate when the function of the system 
becomes altered. 
In the nigrostriatal pathway, the DA signal is primarily terminated by the 
re-uptake through the dopamine transporter (DAT) in an ion dependent manner 
(Figure 1.4) (Hoffman et al., 1998). DAT is located at the periphery of the 
presynaptic nerve terminal in the nigrostriatal pathway and functions to remove 
DA from the extracellular space before it escapes the synaptic cleft (Kuhar et al., 
1990; Graham and Langer, 1992). A portion of the DA that is transported into the 
neuron terminal by DAT is repackaged into vesicles for release, but cytosolic 
enzymes can also metabolize cytosolically available DA.  
The DA signal is also terminated through the metabolism of DA. Enzymes 
for DA metabolism are located extrasynaptically and intrasynaptically. Therefore, 
DA in the cytosol or extracellular space has the potential to be metabolized. DA  
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Figure 1.4 Dopamine Reuptake and Metabolism 
Dopamine is removed from the synapse through reuptake by the DAT or 
metabolism by extraneuronal enzymes. DA can be metabolized intraneuronally 
by MAO A and ALDH or extraneuronally by COMT and/or MAO B. Metabolism of 
DA by MAO / ALDH produces DOPAC and metabolism by COMT produces 3-
MT, which can be converted to HVA by MAO. 
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metabolites include 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid 
(HVA), and 3-methoxytyramine (3-MT). In the rat the primary metabolite of DA is 
DOPAC, but in primates HVA is the primary metabolite (Kopin, 1994). There are 
three enzymes primarily responsible for the metabolism of DA monoamine 
oxidase (MAO), aldehyde dehydrogenase (ALDH), and catechol-o-
methyltansferase (COMT). 
MAO is divided into two categories, A and B, based on localization and 
substrate preference. In the striatum MAO-A is primarily localized to the outer 
mitochondrial membrane in dopaminergic neurons and MAO-B is localized 
extraneuronally (Kopin, 1985; Shih et al., 1999). Both forms of MAO catalyze the 
conversion of DA to the corresponding aldehyde upon which ALDH acts. ALDH is 
localized to the cytoplasm and inner mitochondrial leaflet and functions to oxidize 
aldehydes to their corresponding acids (Tank et al., 1981). In this manner, DA is 
converted to DOPAC. COMT is primarily a membrane bound enzyme in the CNS 
and is responsible for the metabolism of DA to 3-MT. Generally, 3-MT is only 
present in small quantities because it readily interacts with MAO and ALDH to 
form HVA (Iversen, 2009). The modification of the metabolic processes/enzymes 
modifies DA availability for release and signaling. The degree of DA signaling 
activity is dependent on synthesis, packaging, release, reuptake, and 
metabolism, and alterations of these processes modify the function of the entire 
nigrostriatal pathway and potentially the entire basal ganglia. 
Parkinson’s Disease 
In 1817 PD was first described by the man from whom its name is derived, 
James Parkinson (Reprint: Parkinson, 2002). However, the disease can be 
traced back to approximately 1500 – 2500 B.C. PD is divided into two 
subcategories: idiopathic and familial, based on the pathogenesis of the disease. 
The etiology of idiopathic PD is generally theorized to involve genetic and 
environmental components that begin the progressive neuronal loss 
demonstrated by the disease (Thomas, 2009). Familial PD is caused by genetic 
mutations and related protein dysfunctions. Familial PD presents with similar 
symptoms as idiopathic PD, but has an earlier age of onset  (Bajaj et al., 1998). 
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The focus of this dissertation is on therapeutic interventions in idiopathic PD, 
which may also have implications on familial PD.  
The primary risk factor for development of idiopathic PD is age, with 4% of 
the population over age 65 experiencing parkinsonism. There are four cardinal 
motor features related to PD; resting tremor, bradykinesia, rigidity, and postural 
instability (Wichmann and DeLong, 2003). The motor symptoms can become 
debilitating as the disease progresses, but cognitive symptoms such as 
depression and dementia can manifest as well (Kummer and Teixeira, 2009; 
Lohle et al., 2009). Greater than 47% of patients diagnosed with PD exhibit 
depression symptoms often predating their motor symptoms. The cognitive 
decline associated with PD is related to the age of the individual; 65% of patients 
over age 85 exhibit signs of dementia (Davis, 2002). The disruption of basal 
ganglia function by the dysfunction of the nigrostriatal pathway is assumed the 
primary cause of the motor manifestations, but it is not the primary cause of the 
psychiatric and cognitive alterations associated with PD.  
The hallmark of PD is a loss of the dopaminergic neurons in the 
nigrostriatal pathway with greater than a 60% reduction of dopaminergic neurons 
in the SN (Gibb and Lees, 1991). Dopaminergic neuronal loss in conjunction with 
dysfunction of the remaining neurons contributes to an 80% or greater reduction 
in DA content. A pathological hallmark of PD is the presence of Lewy bodies, 
protein aggregates, which are generally deposited in the cell bodies of 
dopaminergic neurons. These protein aggregates are thought to contribute to the 
neuronal loss and dysfunction because they coincide with areas of the most cell 
death (Bethlem and Den Hartog Jager, 1960; Gibb and Lees, 1989). The loss of 
dopaminergic neurons extends beyond the SN but is not as severe in any other 
region of the brain. Other areas in the brain also demonstrate damage, especially 
other midbrain catecholaminergic neurons, such as the locus coeruleus and 
dorsal raphe (Braak et al., 2003; Braak et al., 2004; Braak and Del Tredici, 2008). 
PD inexorably progresses generally over 10 - 20 years with continued neuron 
loss in the nigrostriatal pathway. As the disease progresses, multiple 
neurotransmitter systems begin to experience neuronal loss extending to cortical 
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systems (Hawkes et al., 2009). Intervention strategies for PD range from surgical 
interventions like deep brain stimulation to the continued use of L-dopa, a 
chemical replacement therapy. Drug therapies for PD will be discussed in more 
detail later in this chapter but primarily focus on restoring dopaminergic function 
in the nigrostriatal pathway. Restoration of the DA deficit in the nigrostriatal 
pathway is known to alleviate some of the motor symptoms associated with PD. 
Therefore, our studies will focus on the modulation of dopaminergic function, 
which could potentially alleviate some of the motor symptoms related to PD. 
Rodent Models of Dopaminergic Dysfunction 
Rodent models of dopaminergic dysfunction have been developed to aid 
in the understanding of the progression and development of PD as well as to test 
potential therapeutics. Numerous methods are currently employed to produce 
animals that model components of PD. One of the oldest and most widely used 
models uses 6-hydroxydopamine (6-OHDA) to produce dopaminergic neuronal 
loss (Ungerstedt, 1973; Ungerstedt et al., 1974; Ungerstedt, 1976). 
Catecholaminergic neurons are targeted by 6-OHDA by neuronal uptake through 
the catecholamine transporters such as the norepinephrine transporter or the 
DAT. 6-Hydroxydopamine induced cell death is mediated by the autooxidation of 
6-OHDA producing quinones, peroxide, superoxide and hydroxyl radicals (Sachs 
and Jonsson, 1975; Schwarting and Huston, 1996). Molecules produced from 6-
OHDA are highly reactive and can damage proteins, disrupt the mitochondrial 
membrane, and damage DNA. Neurotoxin damage induces degeneration of the 
dopaminergic neurons that peaks at approximately 2 weeks after the injection 
and stabilizes by 4 weeks  (Leak and Zigmond, 2008). Cell death induced by 6-
OHDA can be used to model the neuronal loss demonstrated in PD. To mimic 
the cell loss at different stages of PD, 6-OHDA-induced cell death can be 
modulated through the site and volume of the delivered neurotoxin. 6-
Hydroxydopamine induced neuronal loss does not produce Lewy bodies or 
progress in a similar manner to PD, but can provide a model with similar 
dopaminergic neuron loss and correlative motor impairments. The 6-OHDA 
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model provides controllable, specific dopaminergic cell loss that is well 
characterized.  
Discovery of genetic linkages to PD and the development of technology to 
produce genetically modified mice converged to allow the production of multiple 
mouse models of various components of PD (Polymeropoulos et al., 1996; 
Matsumine et al., 1997). Genetic models of PD are generally related to 
dysfunction of mitochondria, protein degradation, and reactive oxygen species 
regulation. Genetic models of PD do not generally produce the neuronal loss in 
the nigrostriatal dopaminergic system, associated with PD (Goldberg et al., 2003; 
Von Coelln et al., 2004; Kitada et al., 2007). These mouse models provide the 
opportunity to investigate genetic components that could be contributing to the 
development of PD.  
Many of the genetic models do not show dramatic dopaminergic 
dysfunction and are not responsive to DA replacement therapeutics. Neurotoxin 
induced denervation models demonstrate responsiveness to L-dopa and provide 
a loss of dopaminergic neurons in the nigrostriatal pathway equivalent to that of 
PD (Robertson and Robertson, 1988, 1989; Kirik et al., 1998; Lindgren et al., 
2007). Therefore, in the studies within this dissertation I used 6-OHDA induced 
models of DA denervation.  
Parkinson’s Disease Drug Therapies 
DA therapeutic drugs generally focus on the replacement of the lost 
neurotransmitter. There are multiple ways to enhance or replace DA in the CNS 
such as blocking metabolism of DA, increasing DA synthesis, or using DA 
receptor agonists to provide post-synaptic stimulation (Iversen, 2009). DA 
replacement therapy by administration of some form of L-dopa / carbidopa is the 
most common treatment of PD and has been used extensively with positive 
results since its inception in the late 1960s (Diaz and Waters, 2009). L-dopa 
therapy has been implicated in the development of dyskinesias after long-term 
therapy with the short half-life of the drug contributing to the motor fluctuations. 
Also, L-dopa therapy commonly begins to lose effectiveness after 5 years as the 
neuronal loss progresses (Goudreau, 2006; Muller and Russ, 2006). Other 
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therapies focusing on MAO or COMT inhibition rely on an intact dopaminergic 
synapse to produce DA and as primary therapies become ineffective as the 
neuronal loss increases (Cedarbaum et al., 1990). These therapies can increase 
the effectiveness of L-dopa therapy by modulating its breakdown and increasing 
the half-life, but their reliance on L-dopa eventually renders them ineffective. DA 
receptor agonists can also be used as monotherapies in early symptomatic 
stages of PD but generally are used in conjunction with L-dopa to maintain a 
steady activation of DA receptors (Nutt, 1998). In later stages, most of the drug 
therapies for PD are dependent on co-delivery with L-dopa for lasting beneficial 
effects. Treatment of PD is still maintained through a 40-year old drug 
replacement therapy that does little to modify the progression of the disease. In 
this dissertation, the focus will be on treating the underlying problem of 
progressive neuronal loss to restore function to the nigrostriatal pathway. 
GDNF Development as a Potential Therapeutic 
GDNF was identified in 1993 from a glial cell line and shown to have 
neurotrophic properties on midbrain dopaminergic neurons (Lin et al., 1993). 
GDNF is a member of the transforming growth factor-β superfamily, 
characterized by seven cysteine residues and mature protein dimerization. 
GDNF is the originator of the subfamily of GDNF family ligands including 
Neurturin, Artemin, and Persephin (Peterziel et al., 2007). GDNF family ligands 
signal through a shared receptor family the GDNF family receptor α (GFRα) 1 – 
4, which are coupled to Ret tyrosine kinase. GDNF primarily signals through 
GFRα-1 activating Ret tyrosine kinase and signaling downstream through the 
Erk/MAPK pathway (Sariola and Saarma, 2003). 
GDNF demonstrated potential as a therapeutic for PD by enhancing and / 
or partially restoring dopaminergic neuron function in rodent models of 
dopaminergic dysfunction (Hoffer et al., 1994; Wang et al., 1996; Hebert and 
Gerhardt, 1997; Rosenblad et al., 2000; Kirik et al., 2001). In the normal Fischer 
344 rat, a single intranigral delivery of GDNF increased basal concentrations of 
DOPAC and HVA in the striatum. Simultaneously, potassium and d-
amphetamine evoked releases were also increased within the striatum (Hebert et 
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al., 1996). Intranigral GDNF delivery in aged rats increased basal concentrations 
of DA, DOPAC, and HVA, while increasing potassium and d-amphetamine 
evoked DA release (Hebert and Gerhardt, 1997). Hoffer et al. showed GDNF 
treatment reduces apomorphine-induced rotation behavior and increases DA and 
DOPAC content in the SN of rat with greater than a 90% loss of dopamine. 
GDNF partially restored dopaminergic function in dysfunctional model systems, 
the aged rat, and dopamine depleted model systems, the lesioned rat. GDNF 
improves neurochemical function, which leads to improved behavioral 
performance in rodents. The positive effects of GDNF treatment on rodent 
dopaminergic systems provided the necessary supporting evidence to begin 
investigation in non-human primates.  
  Intraventricular treatment of parkinsonian non-human primates with 
GDNF greatly improved behavioral and neurochemical function with increased 
neuronal sprouting within the SN (Gash et al., 1996; Zhang et al., 1997; Grondin 
et al., 2002). GDNF treatment: increased dopamine content within the SN, VTA, 
and globus pallidus, improved the parkinsonian features of bradykinesia, postural 
instability, and rigidity, and increased TH+ positive neuron size and density in the 
SN. Initially, GDNF entered into phase I clinical trials using intraventricular 
delivery, but was unable to alter PD related behavioral deficits. Intraventricular 
delivery of GDNF still demonstrated biological activity through its multiple side 
effects such as nausea, Lhermite’s sign, inappropriate sexual behavior, 
hallucinations, and depression (Kordower et al., 1999; Nutt et al., 2003). Because 
of the positive preliminary work with GDNF, it was concluded that the 
intraventricular delivery system was the primary problem and other methods and 
areas of delivery needed to be explored. 
Intranigral delivery of GDNF in normal non-human primates increased 
activity levels and increased potassium-evoked dopamine release. Investigation 
of tissue neurochemical levels in the same animals demonstrated increases in 
DA and HVA in the SN and VTA (Gash et al., 1995). Intraputamenal delivery was 
determined to be an effective means of delivery with distribution of GDNF a key 
component of successful treatment (Grondin et al., 2002; Ai et al., 2003; Gash et 
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al., 2005). Intraputamenal delivery of GDNF in parkinsonian non-human primates 
improved motor function, increased striatal tissue levels of DA, DOPAC, and 
HVA, and increased TH+ neuron density within the striatum (Grondin et al., 
2002). In the aged non-human primate intraputamenal GNDF treatment, 
increased TH+ fiber density in both the SN and striatum further validated the 
putamen as an effective delivery site (Ai et al., 2003). 
Increased knowledge on delivery and distribution spurred the 
reintroduction of GDNF to phase I clinical testing. In two different phase I trials, 
GDNF showed positive behavioral results with only minor difficulties primarily 
related to the catheter delivery system (Gill et al., 2003; Slevin et al., 2005). 
GDNF progressed into phase II clinical trials, which were abandoned after a lack 
of positive clinical results, and potential neurotoxic effects on the cerebellum 
within the non-human primate (Lang et al., 2006; Hovland et al., 2007). Technical 
differences in drug-delivery between the phase II trial and both phase I trials 
were possible reasons for the discrepancy in results. Differences in delivery and 
distribution of GDNF within the putamen could have potentially reduced the 
efficacy of GDNF to combat PD. Therefore, a small molecule with neurotrophic 
actions similar to GDNF, which can be administered orally or nasally, with no 
toxic effects, could be of great value in the treatment of PD. 
Bioactive Peptide Formation and Neurotrophic Factors 
Nerotrophins are generally large complex molecules with molecular 
properties limiting their bioavailability. The potential of neurotrophins to combat 
neurodegenerative disease has led to intense investigation of their function, but 
more recently, the proregions of growth factors such as BDNF and NGF have 
demonstrated functional significance. Small bioactive molecules are of interest in 
the development of a potential therapeutic because it should have increased 
bioavailability and therefore, increased functional impact. Post-translational 
processing of proBDNF to mature BDNF allows the classically defined signaling 
action TrkB activation, which regulates cell survival, differentiation, and signaling 
function. However, when proBDNF is secreted without post-translational 
modification, apoptosis can be induced through the p75NTR/ sortilin complex 
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(Teng et al., 2005a). The endoproteolytic cleavage of proNGF also regulates 
receptor affinities for p75NTR or TrkA. Therefore, the functional effects of BDNF or 
NGF are regulated by the post-translational processing of the precursor protein, 
which shows that a single proprotein may have differential effects enacted 
through processing (Lee et al., 2001; Nykjaer et al., 2004). The proteolytic 
cleavage of the proNGF molecule at dibasic cleavages sites releases two 
bioactive peptides from the prodomain of NGF that bind tyrosine kinase receptors 
similarly to their precursor protein and provide neuroprotection against excitotoxic 
lesions (Dicou et al., 1997; Dicou, 2006). Neuropeptide proenkephalin A has 
biological activity in opiod neurotransmission, but when post-translationally 
processed at dibasic cleavage sites, studies show the production of multiple 
bioactive peptides from the precursor protein with variable effects on cell 
signaling and neurotransmission. The post-translational processing of precursor 
proteins to produce multiple bioactive peptides, that may have therapeutic value, 
is evidence of the production of diverse signaling molecules originating from a 
single proprotein (Haskins et al., 2004; Bernay et al., 2009).  
 A theoretical model of the post-translational processing of GDNF predicts 
the production of three peptides of which one has been proven to have 
bioactivity, Brain Excitatory Peptide (BEP) (Glass, 2004; Immonen et al., 2008) 
(Figure 1.4). Immonen et al. demonstrated rodent BEP could increase excitatory 
post-synaptic potentials of the rat hippocampal slice. We have synthesized the 
human homolog of the three peptides and we have designated these as 
Dopamine Neuron Stimulating Peptides (DNSPs).  
GDNF, the DNSPs’ precursor protein, has exhibited profound effects in 
the rodent dopaminergic system; therefore, we will begin our initial 
characterization of the DNSPs examining dopaminergic neurotransmission in the 
nigrostriatal pathway. Investigation of GDNF has yielded many positive results in 
protecting and increasing function of neurons in rodent and cell culture models of 
dopaminergic loss (Lin et al., 1993; Hoffer et al., 1994; Kearns and Gash, 1995; 
Tomac et al., 1995b). The successful translation of such a trophic factor to a 
therapy would provide a significant advancement in the ability to treat 
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Figure 1.5 Theoretical Post Translational Processing of GDNF 
The proprotein form of GDNF is theorized to be processed to DNSP-11 and 
DNSP-5 through post-translational modification through multiple enzyme 
interactions. GDNF is potentially modified post-signaling by enzymatic reactions 
to DNSP-17. All of the DNSPs are amidated, potentially altering in vivo stability.  
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Monooxygenase                                  SPDKQMAVLPRR/E 
RNRQAAAANPENSRGKGRR/GQRGKNRGCV 
LTAIHLNVTDLGLGYETKEELIFRYCSGSCD 
AAETTYDKILKNLSRNRRLVSDKVGQACCR 
PIAFDDDLSFLDDNLVYHILRKHSAKRCGCI 
ERNRQAAAANPENSRGKG 
Mature GDNF After Signaling?? 
ERNRQAAAANPENSRGK-amide DNSP-17 } 
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neurodegenerative disease by preventing neuronal loss and/or restoring function 
of damaged neurons (Peterson and Nutt, 2008). Negative results provided by 
clinical investigation of GDNF are accounted for by the difficulties with delivery, 
distribution, or specificity (Lang et al., 2006; Salvatore et al., 2006; Hovland et al., 
2007; Morrison et al., 2007). DNSPs have the potential to rectify many of the 
difficulties associated with GDNF by their ease of manufacturing and potential 
administration through oral or nasal routes. In addition, modifications can be 
made to the DNSPs to increase distribution and specificity. However, the effects 
of the DNSPs on DA neurons must first be understood to determine if and what 
modifications may be necessary. 
Thesis Outline 
Hypothesis: Dopamine Neuron Stimulating Peptides will modulate DA 
neurochemistry in the nigrostriatal pathway analogous to GDNF. 
GDNF has been established as the most effective neurotrophic factor at 
increasing the functional capacity of dopaminergic neurons and is the “gold 
standard” to which other neurotrophins are compared. However, GDNF has not 
been without problems, especially concerning bioavailability and delivery 
methods. The DNSPs may have similar effects on dopaminergic neurons as 
GDNF and would potentially provide increased bioavailability and ease of 
delivery. Therefore, the effects of the DNSPs on DA neurochemical function 
needed to be assessed and compared to previous results with GDNF. The 
primary endpoints of interest were neurochemical measures using whole tissue 
dopamine content or microdialysis collected dopamine concentrations. 
Behavioral and immunohistochemical techniques were applied to explore the 
effects of DNSP altered DA function and were considered supporting data for the 
neurochemical measures. All data were examined relative to previous results 
with GDNF providing a benchmark for the effectiveness of the DNSPs. 
In this thesis, I will discuss the investigation of the DNSPs and their effects 
on dopamine neurochemistry in the nigrostriatal pathway. The goal of these 
studies was to determine if any of the DNSPs can modulate dopaminergic 
neurotransmission analogous to GDNF and characterize their effects. To 
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investigate the DNSPs effects on the damaged dopaminergic system, multiple 
models with varying degrees of dopaminergic dysfunction were treated with the 
DNSPs and their neurochemical function examined. In Chapter 3, the dosage of 
the combined delivery of all three DNSPs was investigated, as was the activity of 
the individual DNSPs on dopaminergic function. Analysis of 3- 6 month Fischer 
344 rats 28 days after receiving intranigral DNSP delivery showed increased 
baseline concentrations of DA, DOPAC, and HVA as well as increased K+ and d-
amphetamine evoked DA release as measured by microdialysis. All 
concentrations of the DNSP mixture altered DA neurochemistry, but the 30 µg 
dose delivered to the SN was found to be most effective. Effects of treatment 
with the individual DNSPs were then investigated to minimize confounding 
factors within the data. DNSP-11 produced significant modifications of DA in the 
striatum 28 days after treatment. DNSP-11 increased baseline concentrations of 
DA, DOPAC, and HVA and increased evoked DA release by K+ and d-
amphetamine. Acute effects of DA were also investigated in the normal Fischer 
344 rat because the rat homolog was demonstrated to stimulate increases in 
post-synaptic potentials   (Immonen et al., 2008). Multiple concentrations of 
DNSP-11 were delivered in the striatum via reverse microdialysis with no change 
in DA concentration until the 1 mM concentration of DNSP-11 stimulation 
increased the basal concentrations of DA with no change in metabolite 
concentrations. DNSP-11 was effective in modulating DA neurochemistry in the 
normal rats, which demonstrated the functional activity of DNSP-11. 
In Chapter 4, the aged (24-month) Fischer 344 rat was used as two 
models of dopaminergic dysfunction. Aged rats received a bilateral infusion of 
DNSP-11 and DA neurochemistry was examined by striatum microdialysis and 
whole tissue neurochemical analysis. DNSP-11 decreased the baseline 
concentration of DA, DOPAC, and K+ evoked release of DA. Modulation of DA by 
DNSP-11 maintained the premise of functional activity by the prodomain 
molecule but was not evidentiary of a therapeutic capacity. 
Chapter 5 continues the investigation of DNSP-11 in a model of 
dopaminergic dysfunction using 6-OHDA neurotoxin to create neuroprotection 
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and neurorestoration study paradigms. In the neuroprotection model, DNSP-11 
did not provide neuroprotective effects but did modulate neurochemistry by 
enhancing DA metabolism. In the neurorestoration model, DNSP-11 enhanced or 
restored function to dopaminergic neurons 28 days after a single injection to the 
SN. DNSP-11 reduced apomorphine-induced rotation behavior and increased DA 
and DOPAC nigral tissue content. A reduction in rotation behavior was the first 
documented occurrence of a behavioral modification by DNSP-11 treatment. 
Similar to previous results with GDNF, DNSP-11 was seen to increase function of 
normal and dysfunctional DA neurons over 4 weeks after a single intranigral 
administration. 
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Chapter Two: Methods 
Chemicals 
All chemicals were purchased from Fisher Scientific (Fisher Chemical 
Fairlawn, NJ) except for liquid chromatography grade chemicals purchased from 
Sigma-Aldrich (St. Louis, MO). The DNSPs were synthesized and purified by 
W.M. Keck Foundation, Yale University (New Haven, CT).  
Animals and Procedures  
 Male Fischer 344 (F344) rats were used in all experiments to reduce 
hormone interference with neurochemical function, and cellular interactions of the 
DNSPs. F344 rats are an inbred rat strain, which reduces the variability of study 
measurements due to minimization of genetic variation. Prior work shows GDNF 
increased dopaminergic function in the F344 rat and provides precedence for 
trophic activity and is a benchmark for DNSP activity (Hoffer et al., 1994; 
Bowenkamp et al., 1995; Hebert et al., 1996; Hebert and Gerhardt, 1997). F344 
rats are commonly used as a model of aging and have significant reductions in 
motor functions that are related to dopaminergic dysfunction (discussed in detail 
in Chapter 1). Therefore, aged F344 rast (older than 22 months) were used as a 
model of dopaminergic dysfunction in the studies described within this 
dissertation (Shimokawa et al., 1993). All rats were obtained from Harlan 
Laboratories Inc. (Indianapolis, IN), but the aged (24 months old) rats originate 
from the National Institute on Aging Colony. Animals were housed in the 
Department of Laboratory Animal Research Facility on a 12 hr light/dark cycle 
with food and water provided ad libitum. All behavioral and neurochemical 
measures were performed in the 12 hr light portion of the cycle. All animal 
procedures were reviewed and approved by our Institutional Animal Care and 
Use Committee (IACUC) and conform to AAALACI guidelines. 
Surgical Procedures 
Survival surgical procedures were performed under continuous delivery of 
1.5% - 2.5% isoflurane in a sterilized laminar flow hood. Sterilization and pain 
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management techniques were followed according to protocols approved by 
IACUC. After all survival surgeries animals were allowed to recover in their home 
cage and provided with pain relief for 72 hours or until euthanasia using 5 mg/kg 
carprofen subcutaneously delivered every 24 hours. 
Non-survival surgical procedures were performed under urethane (1.25 
mg/kg).  
Infusion Delivery of DNSPs 
The skin above the skull was reflected and a single burr hole drilled to allow 
access to two points. The following stereotaxic coordinates from bregma were 
used to deliver the infusion solutions: Point #1 Tooth Bar (TB): -2.3mm, anterior 
posterior (AP): -5.6 mm, medial lateral (ML): -1.7 mm, dorsal ventral (DV): -7.3 
mm and Point #2 TB: -2.3 mm, AP: -5.6 mm, ML: -2.5 mm, DV: -6.8 mm (Hebert 
et al., 1996; Paxinos and Watson, 2005) (Figure 2.1A). DNSPs were dissolved in 
pH 5 Citrate Buffer (150 mM NaCl and 10 mM Sodium Citrate). The DNSP 
solution or citrate buffer vehicle was delivered unilaterally to the nigral cell bodies 
through the burr hole to the two aforementioned stereotaxic coordinates using a 
22-gauge tip style 3 Hamilton syringe (Hamilton Company USA, Reno, NV) 
connected to a 25 µL gas tight syringe. The individual performing the infusion 
was blinded to the content of the delivered solution. The doses for the DNSPs 
are detailed in each chapter. An infusion rate of 0.25 μL/min over 10 minutes was 
controlled by a KD Scientific model 100 infusion pump (KD Scientific Inc., 
Holliston, MA) to deliver 2.5 μL of the blinded treatment solution to the two points 
dorsal to the SN. A total of 5 μL of solution was delivered to the SN. A five minute 
wait period between needle insertion and solution delivery was carried out to 
allow normalization of the tissue. A 10 minute wait period between solution 
delivery and needle removal was carried out to prevent concentrating the solution 
in the needle track. Delivery to the second infusion point used the same burr hole 
and followed similar methodology as the first point. Bone wax was used to cover 
the burr whole and the animals surgical site was closed using dissolvable 
sutures. 
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Figure 2.1 Neuroanatomical Location of SN Infusions and 
Microdialysis Probes 
A) (RED) Representation of the path of needle insertion used to deliver the 
DNSPs dorsal to the dopaminergic cell bodies located within the SN. B) The 
microdialysis probe membrane (GREY) spans the dorsal / ventral length of the 
striatum sampling the extracellular space at the dopaminergic terminals. Modified 
from (Paxinos and Watson, 2005). 
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Delivery of 6- Hydroxydopamine to the Medial Forebrain Bundle and 
Infusion of DNSP-11 or Vehicle 
An extensive DA lesion was produced by lesioning the nigrostriatal 
pathway with 6-OHDA. Adult F344 (3-6 month) rats were administered 
desipramine (30 mg/kg i.p.) in physiological saline at the onset of the procedure 
to maintain dopaminergic neuron specific toxicity. Rats were placed in a 
stereotaxic frame, the skin above the skull reflected, and a single burr hole was 
drilled into the skull. The burr hole was oriented to allow access to two injection 
sites along the MFB with the following stereotaxic coordinates: Point #1 TB: -2.4 
mm, AP: -4.4 mm, ML:  -1.2 mm, DV: -7.1 mm, Point #2 TB: +3.4 mm, AP:-4.0 
mm, ML: -0.8 mm, DV: -8.0 mm (Lundblad et al., 2002; Paxinos and Watson, 
2005). 6-OHDA was injected into the MFB using a 3.6 µg/µL 6-OHDA•HCl 
solution with 0.9% NaCl and 0.02% ascorbic acid. The 6-OHDA solution was 
injected using a 10 µL 22-gauge tip style 3 Hamilton syringe. The first point 
targeted neurons projecting from the SN (A9 pathway) with an injection of 2.5 µL 
of the 6-OHDA solution and the second point targeted neurons projecting from 
the ventral tegmental area (A10 pathway) with an injection of 2.0 µL of the 6-
OHDA solution. The burr hole was covered with bone wax and the surgical site 
was closed using dissolvable sutures. The lesion was allowed to progress for 
four weeks and the animal’s health was closely monitored. Four weeks after the 
lesions, the severity of the lesion was tested using apomorphine-induced (0.05 
mg/kg s.c.) rotation behavior, which will be discussed in detail later in this 
chapter. 
Five weeks after the unilateral 6-OHDA delivery, animals were grouped 
based on their prescreen rotation values while maintaining equal apomorphine 
induced rotation behavior between groups. Animals received either a 100 µg/5 
µL DNSP-11 solution in citrate buffer or the vehicle solution, citrate buffer, with 
the solution content blinded to the person performing the infusion. An infusion 
protocol was followed identical to the previous section, Infusion Delivery of 
DNSPs, with delivery to the SN ipsilateral to the delivery of 6-OHDA. An infusion 
rate of 0.25 μL/min over 10 minutes was used to deliver 2.5 μL of the blinded 
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treatment solution to each of the two points for a total of 5 µL delivered to the SN. 
All rats’ apomorphine-induced rotation behavior was assessed weekly for four 
weeks. One week after the last rotation session animals were sacrificed and their 
SN and striatum dissected out for analysis of neurochemical content. Both 
rotation behavior and neurochemical content analysis will be discussed more 
thoroughly in subsequent sections within this chapter. 
Striatal Delivery of 6- Hydroxydopamine and DNSP-11  
Normal Young (3-6 month) Fischer 344 rats were anesthetized under 
isoflurane and treated in a blinded manner with 100µg/3µL of DNSP-11 or 3 µL of 
citrate buffer vehicle. Infusion treatment was delivered over 3 minutes using a 10 
µL 22-gauge tip style 3 Hamilton syringe placed into the brain at the following 
stereotaxic coordinate within the striatum; TB: 0.0 mm, AP: +1.0 mm, ML: -3.0 
mm, DV: -5.0 mm (Kirik et al., 2000; Paxinos and Watson, 2005). After drug 
infusion treatment, a five-minute wait period was used to allow diffusion of the 
delivered solution and the animal was allowed to recover from anesthesia.  
Six hours after infusion delivery of vehicle or DNSP-11, animals were 
anesthetized again and injected with 20µg/3µL of 6-OHDA•HCl in physiological 
saline containing 0.02% ascorbic acid. The 6-OHDA was infused over three 
minutes to the same striatal coordinates as the treatment using a10 µL 22-gauge 
tip style 3 Hamilton syringe. A five-minute wait period was carried out after 
infusion to allow diffusion of 6-OHDA and then the incision was closed using 
dissolvable sutures.    
Microdialysis 
Microdialysis can be used to sample the content of the extracellular space 
and simultaneously deliver solutions of interest (Figure 2.2). Simultaneous 
delivery and collection  allows the quantification of multiple neurochemicals under 
multiple conditions (Hocht et al., 2007). Microdialysis uses a porous membrane 
on the tip of a hollow steel shaft allowing for diffusion of molecules from the 
extracellular space into the fluid flowing through the probe (Ungerstedt and 
Hallstrom, 1987). 
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Figure 2.2 Microdialysis Membrane Function 
Microdialysis provides delivery of the perfusion solution (GREEN) and 
simultaneous sampling of the extracellular neurochemicals (PINK) relative to 
their respective concentration gradients.  
 
 
Courtesy of CMA Microdialysis 
http://www.microdialysis.se/products 
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Figure 2.3 Microdialysis Probes Images and Descriptions 
Depiction of CMA 11 and CMA 12 microdialysis probes. The CMA 11 probe has 
a 4mm Cuprophane membrane with a 6,000 Dalton molecular weight cut-off and 
0.38 mm shaft diameter. The CMA 12 probe has a 2mm Polyarylethersulfone 
membrane with a 20,000 Dalton molecular weight cut-off and a 0.64mm shaft 
diameter.  
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In the studies discussed in this document two types of microdialysis 
probes were used, CMA 11 and CMA 12 (Figure 2.3), with their primary variation 
being membrane length and molecular cut-off. The membrane length was 
changed based upon the brain structure of interest and the molecular weight cut-
off was varied based upon the size of the molecules of interest. Rate of recovery 
and delivery of molecules of interest is relative to the concentration gradient of 
the chemicals delivered and those being sampled. Recovery and sampling rates 
can be manipulated by modifying the sample collection time and fluid flow rate. A 
balance between optimal recovery, sample volume, and collection time needs to 
be achieved to maintain sensitivity and resolution to neurochemical changes (Li 
et al., 2006).  
Microdialysis Probe Preparation and Probe Recovery Determination 
A KD Scientific model 230 pump in conjunction with 1mL Hamilton 
syringes (point style 3) were connected to a CMA 11 microdialysis probe via FEP 
tubing. Microdialysis probes were flushed with 70% ethanol for a minimum of 4-5 
minutes to remove the glycerol packing solution from the probe membrane. 
Probes were then flushed with deionized water for 4-5 minutes to remove the 
ethanol and prevent salt crystal formation. Probes were soaked in deionized 
water until preparations were made to determine the percent recovery rate for the 
neurochemicals of interest. The percent of recovery for each probe was 
determined by perfusing the probes with artificial cerebral spinal fluid (aCSF) 
(124 mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM NaH2PO4) as the 
probe was submerged in a solution containing standardized concentrations of the 
following neurochemicals: 2 x 10-7 M NE, 1 x 10-7 M DOPAC, 2 x 10-7 M DA, 1 x 
10-7 M HVA, 2 x 10-7 M 5-hydroxytryptamine (5-HT), and 4 x 10-7 M 5-
hydroxyindoleacetic acid (5-HIAA). Neurochemical concentrations were 
measured by high performance liquid chromatography coupled with 
electrochemical detection (HPLC-EC). The percentage of neurochemicals in the 
collected solution relative to the standard solution yields the neurochemical 
percent recovery. 
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Microdialysis in DNSP pretreated rats 
Twenty-eight days after treatment with DNSPs, animals were anesthetized 
with urethane (1.25 mg/kg i.p.) and placed in a stereotaxic frame. A craniotomy 
was performed to place the CMA 11 microdialysis probe within the striatum using 
the following stereotaxic coordinates: from bregma AP: +1.5 mm ML: -2.3 mm 
DV: -8.0 mm (Hebert et al., 1996; Hebert and Gerhardt, 1997; Paxinos and 
Watson, 2005)(Figure 2.1B). Perfusion solutions included aCSF, 100 mM K+ 
aCSF (26 mM NaCl, 100 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM NaH2PO4), 
or 250 μM d-amphetamine aCSF all within the pH range of 7.2 -7.4. All solutions 
were perfused at a rate of 1 μL/min with a sampling time of 20 minutes yielding 
20 μL fractions. The first 20-minute fraction after placement of the probe within 
the striatum was discarded because of variability due to damaging synapses 
upon lowering the probe into the brain. (Sample Time 0 - 100 min.) Five total 
fractions were collected, and the perfusate solution was switched to the 100 mM 
K+ aCSF using a CMA liquid switch (CMA 110). (Sample Time 100 – 120 min.) 
The 100 mM K+ aCSF solution was perfused for 20 minutes. (Sample Time 120 
– 200 min.) Upon completion of fraction 6, the solution was switched back to 
aCSF for fractions 7-10. (Sample Time 200 – 220 min.) After fraction 10 was 
collected, the perfusate was switched to d-amp aCSF for 20 minutes. (Sample 
Time 220 – 320 min.) Fraction 11 was collected and the perfusate was switched 
back to aCSF for the remainder of the experiment, fractions 12 – 16. Dialysate 
samples were immediately frozen (-70 ˚C) after collection and thawed just prior to 
HPLC-EC analysis. 
Baseline neurochemical concentrations were calculated for all data sets 
from the average of samples 2-4. The high K+ solution and d-amp containing 
solutions were used to evoke DA release and were compared across treatment 
groups. The 100 mM K+ solution stimulates neurotransmitter release from pre-
synaptic terminals and can provide evidence of changes in vesicle number and 
neurotransmitter content. The d-amp containing solution interacts with the DA 
transporter reversing DA transport and causing neurotransmitter release in a 
calcium independent manner. D-amphetamine-induced neurotransmitter release 
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provides evidence of changes in cytosolic DA content and / or the DA 
transporter. Overall, the microdialysis design we use provides insights into the 
tonic release of DA (baseline), calcium and sodium-dependent release of DA 
(100 mM K+), and calcium-independent release of DA (250 µM d-amphetamine).   
 Reverse Microdialysis of DNSP-11 
F344 rats (3-6 month old) were used for acute DNSP-11 studies 
discussed in Chapter 3, but were given no pretreatment with DNSP-11. Animals 
were anesthetized with urethane (1.25 mg/kg i.p.) and placed in a stereotaxic 
frame. A craniotomy was performed allowing the microdialysis probe to be placed 
into the striatum using the following stereotaxic coordinates: From bregma AP: 
+0.5 mm ML: -3.0 mm DV: -5.5 mm. A KD Scientific model 230 pump in 
conjunction with 1 mL Hamilton syringes (point style 3) was connected to CMA 
12 microdialysis probes (Figure 2.3) via FEP tubing. Microdialysis probes had a 
2.0 mm membrane length and 20,000 Dalton cut-off providing delivery of the 
perfusate and sampling of the extracellular fluid. Perfusion solutions include 
aCSF and varying concentrations of DNSP-11 (3 µM – 1 mM) dissolved in aCSF. 
All solutions were sterile filtered and adjusted to a pH range of 7.2 -7.4. A 
sampling rate of 1 µL/min was used with a sampling time of 20 min yielding 20 µL 
of volume for each fraction. Artificial cerebral spinal fluid was perfused for a total 
of 30 minutes and the dialysate discarded. After 30 minutes of aCSF perfusion, 
dialysate sample collection began every 20 minutes. (Sample Time 0 – 80 min.) 
Fractions 1-4 were collected with aCSF as the perfusate. Immediately following 
the collection of sample 4, the perfusate solution was switched to DNSP-11 in 
aCSF using a CMA liquid switch (CMA 110). (Sample Time 80-160 min.) 
Fractions 5-8 were collected using aCSF containing DNSP-11 as the perfusion 
solution. (Sample Time 160-220 min.) After the collection of fraction 8, the 
perfusate solution was switched back to aCSF for the remainder of the 
experiment, fractions 8 – 11. The neurochemical baseline with aCSF perfusion 
solution was determined by the average of fractions 1-4 (0 – 80 min) and the 
change from baseline caused by DNSP-11 was determined from the average of 
fractions 5-8 (80 – 160 min). Probe recoveries ranged from 25 – 35% with an 
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average of 31.2 ± 0.5%. The raw data were analyzed by a two-way ANOVA and 
fraction 8 was used to produce a dose response curve, analyzed by a one-way 
ANOVA.  
Measurements of Spontaneous Locomotion 
Spontaneous motor activity and movement velocity was assessed by 
automated activity chambers (Omnitech Electronics, Digiscan Animal Activity 
Monitor, Columbus, OH) in 3-6 month old F344 rats treated with 30 µg/5 µL of 
DNSP-11. The automated activity chamber is a 40 x 40 acrylic box with infrared 
beams mounted horizontally every 2.5 cm at both 2 cm and 10 cm from the floor 
(Figure 2.4). For a single testing session, the animal spent 6, ten minute periods 
in the automated activity chamber with the number of beam breaks being 
recorded by a computer (Hebert and Gerhardt, 1997). Motor activity was 
represented by the total distance the animal travels in the specified sampling 
period and average movement speed, which was the distance traveled divided 
by time. All animals were habituated to the activity chambers through four weekly 
testing sessions before treatment. Animals were subsequently divided into two 
groups with comparable spontaneous activity and movement velocity values. 
Animals received DNSP-11 or vehicle as per the previously discussed infusion 
protocol with personnel performing the infusion blinded to the treatment. Both 
groups underwent weekly testing sessions for four weeks after treatment 
comparing total distance and movement speed. Data were analyzed by a two-
way ANOVA with Bonferroni’s post-hoc tests comparing DNSP-11 and citrate 
vehicle treatment over the five testing sessions. 
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Figure 2.4 Assessment of Spontaneous Locomotor Activity 
We used the activity monitors sold by Omnitech to assess spontaneous 
locomotion. Horizontal projecting lasers allow quantification of the movement 
speed and distance traveled based on the interruption of the projected beams. 
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Assessment of Drug-Induced Rotation Behavior  
Drug-induced rotation behavior produced by d-amphetamine and 
apomorphine injections has been used as a method for measuring nigrostriatal 
dopaminergic function in unilateral lesioned rats. Ungerstedt and Arbuthnott 
introduced rotation behavior as a method to study nigrostriatal DA activity and 
hypothesized the behavior was related to imbalances in DA receptor activation 
between the two hemispheres (Ungerstedt and Arbuthnott, 1970). The 
asymmetrical activation of DA receptors has been demonstrated to be 
responsible for rotation behavior with changes in DA receptor function after 
lesion (Sonsalla et al., 1988). Apomorphine and amphetamine rotations have 
been shown to correlate with loss of dopaminergic function, but low-dose (0.05 
mg/kg) apomorphine is highly sensitive to dopaminergic loss above a 90% loss 
threshold and post-synaptic dopamine receptor supersensitivity. Amphetamine 
has a linear relationship with functional DA loss making it less sensitive, but has 
value for predicting mild dopaminergic functional loss (Hudson et al., 1993). In 
the studies discussed within this dissertation, both apomorphine and 
amphetamine rotation behavior was utilized based primarily upon the lesion 
model being used and the sensitivity of rotation behavior provided by each drug. 
Apomorphine-induced rotations were used in conjunction with the extensive 
nigrostriatal lesion and amphetamine rotations were used in conjunction with the 
striatal lesion.   
Apomorphine-Induced Rotational Behavior 
MFB lesion severity was assessed before DNSP treatment using 
subcutaneous injections of 0.05 mg/kg apomorphine to induce rotational behavior 
measured by SDI Rotation software. A thoracic harness connected the rats to a 
counting head that interfaced with the computer and quantified the number of 
ipsi- and contralateral rotations (Figure 2.5). Rotation behavior was quantified for 
two hours in five-minute intervals after apomorphine was administered. Only 
animals exhibiting >200 rotations in the first hour contralateral to the lesion, 
which correlates to a greater than 90% lesion of the nigrostriatal pathway, 
proceeded to further treatment and testing (Hoffer et al., 1994). Beginning one 
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week after DNSP treatment apomorphine (0.05 mg/kg) induced rotation behavior 
was assessed again once per week for four weeks. Because of the 
pharmacological properties of apomorphine, only the first hour of rotation 
behavior was analyzed. The subsequent DNSP treatment group data were 
normalized to the control group and analyzed using a one-way ANOVA with 
Bonferroni’s post-hoc tests.  
Amphetamine-Induced Rotational Behavior 
Striatal lesioned animals generally have a milder loss of dopaminergic 
projections and are less sensitive to apomorphine-induced rotational behavior. 
Therefore, lesion progression was assessed by amphetamine-induced rotational 
behavior. Striatal lesion animals were monitored weekly from week three – week 
six after treatment with 6-OHDA and DNSP-11. After the 6-OHDA and DNSP-11 
treatment, two weeks was allowed to pass to permit progression of the 
dopaminergic cell loss (Kirik et al., 2000). At each behavioral recording session, 
an animal was placed in a thoracic harness, received an intraperitoneal injection 
of 2.5 mg/kg d-amphetamine, and placed in a rotometer bowl. SDI Rotation 
software quantified rotational behavior in five-minute bins over a two- hour 
recording session. Data from the first 20 minutes and last 40 minutes of the 
recording session were discarded and the remaining one-hour block of stable 
rotational behavior was analyzed by a two-way ANOVA with Bonferroni’s post-
hoc tests comparing mean rotational behavior between treatment groups across 
all testing sessions. 
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Figure 2.5 Quantitation of Rotation Behavior 
To assess rotation behavior, animals were placed into rotometer bowls and 
affixed to a thoracic harness. Animals received an injection of apomorphine (0.05 
mg/kg) or d-amphetamine (2.5 mg/kg) based upon the study paradigm. The 
harness was connected to a counting head that interfaced with a computer and 
quantified the direction and number of rotations exhibited by an animal. 
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Cylinder Test for Assessment of Asymmetrical Paw Usage 
A modified version of the cylinder test developed by Schallert et al. was 
used to monitor asymmetric changes in the bilateral nigrostriatal dopamine 
pathways (Schallert et al., 2000). In a darkened room, rats were placed in a 40 
cm tall x 16 cm diameter clear plexiglass cylinder and their movements were 
recorded using a Cannon mini-DVD video recorder for four minutes (Figure 2.6). 
The darkness was used to enhance their activity level and provide greater 
contrast in the video recordings of the rat movements. Rearing behavior was 
analyzed from the video recordings by a blinded observer. Right and left forelimb 
use was distinguished upon rearing and upon landing from the reared posture. 
Forelimb use was quantified one week before DNSP-11 and 6-OHDA lesion 
treatment and at weeks 2 and 4 after treatment (Lundblad et al., 2002). The four-
minute long recording session were viewed by a blinded observer and paw 
usage was quantified by counting the number of times each paw was placed on 
the cylinder walls upon rearing  and upon landing. Data was then normalized to 
the right paw usage (intact hemisphere) and analyzed by a one-way ANOVA with 
Bonferroni’s post-hoc tests.  
Brain Tissue Dissection and Preparation for Neurochemical Analyses 
for Assessment of the DNSPs’ effects on DA Function 
Animals were decapitated while under urethane anesthesia or after 
euthanasia, using CO2 asphyxiation and their brains removed. The brains were 
placed in an ice-cold rat brain matrix where they were sliced into 1 mm sections. 
Visual confirmation of the microdialysis probe placements in the striatum was 
achieved and tissue punches were taken from the dorsolateral striatum using a 
14-gauge blunt tip needle. The SN was dissected out of the most representative 
sections (Figure 2.7). Tissue was placed in pre-weighed microfuge tubes, 
weighed, and recorded. Samples were then frozen on dry ice snow. They were 
stored at -70˚ C (Hudson et al., 1995).  
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Figure 2.6 Modified Schallert’s Cylinder Test for Studies of Motor 
Asymmetry 
A) Modified Schallert’s cylinder test using a Cannon mini-DVD recorder to 
monitor the animals paw use.  
B) The cylinder test assessed asymmetric use of forelimbs after striatal lesion. 
A 
B 
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Figure 2.7 Representative Images of Brain Tissue Slices Showing 
Regions for Neurochemical Analysis  
The above 1 mm tissue slices are representative photographs of the areas 
dissected for HPLC-EC neurochemical analyses and its metabolites. Note the 
striatal tissue punches were taken from the dorsolateral striatum (motor striatum) 
and the nigral tissue was taken from the anterior SN (near infusion points). 
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Tissue Processing for Immunohistochemical studies of TH in DNSP 
Treated Rats 
Tyrosine hydroxylase is an enzyme found in catecholaminergic neurons 
that converts tyrosine to L-DOPA, and is utilized in dopamine, norepinephrine, 
and epinephrine production. Labeling and staining for TH allows catecholamine-
producing neurons to be distinguished within a larger population of neurons. 
Depending on the brain region, specificity for DA neurons can be assumed when 
a small component of the neuron population is noradrenergic or adrenergic 
relative to the DA neuron population. There is  an increased affinity for TH found 
in dopaminergic neurons over TH in noradrenergic neurons (Cuello et al., 1983). 
The sensitivity for TH staining visualization increases in models of dopaminergic 
cell loss because there is a decrease in the variability. TH staining allows 
changes in the number or morphology of DA neurons to be visualized also 
providing evidence of neuronal sprouting and/or restoration. 
Tissue slicing and staining procedures were performed by Yi Ai, MD in the 
lab of Don M. Gash, Ph.D. (Department of Anatomy and Neurobiology, University 
of Kentucky Medical Center). Animals were deeply anesthetized with isoflurane 
and transcardially perfused with heparinized phosphate buffer (0.1 M, PB) 
followed by 4% paraformaldehyde in 0.1 M PB (pH 7.4). Brains were collected 
and post-fixed overnight at 4 oC in 0.1 M PB with 4% paraformaldehyde (pH 7.4). 
Brains were cryoprotected in increasing gradients of phosphate-buffered sucrose 
(15% & 30%) at 4 oC until they sunk. Coronal sections (30-μm-thick) through the 
rostrocaudal extent of the brain were cut on a frozen sliding microtome. Slices 
were collected in a cryoprotectant solution and stored at –20 oC until 
immunocytochemical processing. 
A series of one in every 12th section was immunostained for TH. 
Endogenous peroxidase was blocked with 0.2% hydrogen peroxide for 10 
minutes. Free-floating sections were incubated with primary anti-TH antibody 
(1:2000, Chemicon) overnight at 4 oC and then exposed to biotinylated horse 
anti-mouse secondary antibody (1:1000, Vector) for 1 hour. Sections were then 
incubated in the avidin-biotin-peroxidase complex using the Elite ABC Vectastain 
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Kit (Vector). Visualization of TH immunoreactivity was achieved by using 
3,3’diaminobenzidine as the chromogen with nickel enhancement. In addition, 
two series of adjacent sections were processed for hematoxylin and eosin (H&E) 
and cresyl violet (Nissl) staining for pathological evaluation.  
HPLC-EC Analysis of Dialysate Fractions  
Dialysate fractions were analyzed by HPLC-EC using a pH 4.1 citrate-
acetate buffer mobile phase with 4% methanol and 0.34 mM 1-octane-sulfonic 
acid. At a flow rate of 1.7 mL/ min, analytes of interest were separated using a 
C18 column (4.6 mm x 75 mm, 3 µm particle size, Shiseido CapCell Pak UG120, 
Shiseido Co., LTD., Tokyo, Japan) (Figure 2.8). molecules were detected by 
flowing through a 100 mV conditioning cell before reaching the dual channel 
coulometric detector (ESA model 5014B dual analytical cell) with E1 = +300 mV 
and E2 = -250 mV. Levels of DA, DOPAC, and HVA were quantified based on 
peak area and retention times of known standard concentrations of the analytes. 
This protocol was slightly modified from original work by Hall et al. 1989. 
HPLC-EC Detection and Analysis of Brain Tissue Neurochemical 
Content 
The subsequent description of tissue preparation and respective HPLC-
EC was performed by Stewart Surgener. Whole tissue levels of DA, DOPAC, 
HVA, 5-HIAA, and 5-HT were determined bilaterally in the striatum and SN for 
both DNSP-11 and citrate buffer vehicle groups. Dissected tissue was prepared 
for analysis by addition of an internal standard, dihydroxybenzylamine (DHBA), to 
provide an index of recovery. Tissue was then sonicated in cold citrate-acetate 
buffer mobile phase (pH 4.1) and centrifuged at 16,000 X g for 10 min. 50 µL of 
the subsequent supernatant was injected into the HPLC-EC system. Separation 
of the analytes was achieved by a C18 column (4.6 mm x 75 mm, 3 µm particle 
size, Shiseido CapCell Pak UG120, Shiseido Co., LTD., Tokyo, Japan). The 
mobile phase flow rate was 2.0 mL/min. Detection was carried out using a dual 
channel coulometric detector (ESA model 5011A dual analytical cell) with 
potentials of E1 = +350 mV and E2 = -250 mV. 
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Figure 2.8 HPLC-EC System 
High performance liquid chromatography was used to separate and analyze 
dialysis fractions. Above is an example of the HPLC-EC system, the pump (far 
left) provides flow of the mobile phase carrying injected samples throughout the 
system. The autosampler (center) provides automation of sample delivery and 
precise control over injected sample volumes. The column organizer (far right) 
houses the C18 column, conditioning cell, and detector cell allowing control of 
the temperature and environment in which a sample is separated and detected. 
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The peak area and the retention times of the standards were used to quantify the 
levels of the analytes of interest in the tissue. A more detailed review of this 
protocol can be found in the original work by Hall et al., 1989.  
Brain tissue neurochemical levels were reported as total nanograms in 
sample per gram of the brain tissue wet weight (ng/g wet weight). Tissue 
neurochemical content was analyzed by a one-way ANOVA or Student’s t-test 
depending on the number of groups. The neurochemical content was utilized to 
calculate a ratio of DA metabolism, called the turnover ratio. Turnover ratios were 
calculated from the total DA metabolite content (DOPAC + HVA) divided by the 
DA content. Therefore, the ratio changes as metabolism changes and can be 
used as an indicator of modified metabolic function. Data for each 
neurotransmitter of interest was analyzed by either a one-way ANOVA with 
Bonferroni’s post-hoc tests (more than two treatment groups) or an unpaired two-
tailed t-test (two treatment groups). 
Mitochondrial Isolation and Respiration Assessment 
Mitochondrial isolation and respiration studies were performed by Jignesh 
Pandya, Ph.D. in the lab of Patrick Sullivan, Ph.D. (Department of Anatomy and 
Neurobiology, University of Kentucky Medical Center). The mitochondrial 
isolation procedure was performed at 40C. Rats were anesthetized by CO2 
exposure, their brains were quickly removed, and soaked in a petri dish 
containing mitochondrial isolation buffer (215 mM mannitol, 75 mM sucrose, 
0.1% bovine serum albumin, 20 mM HEPES, 1 mM EGTA; pH adjusted to 7.2 
with KOH) . The striatum was dissected out of each brain and homogenized with 
mitochondrial isolation buffer containing 1 mM EGTA. The homogenized tissue 
was then transferred to microcentrifuge tubes and centrifuged 2 X at 1,300g for 3 
minutes. The resulting supernatant was collected into another set of 
microcentrifuge tubes (while the pellet was saved as the nuclear pellet) and 
centrifuged at 13,000g for 10 min. The supernatant was saved as the cytosolic 
fraction where as the resulting pellet contained enriched crude mitochondria with 
a small synaptosomal portion. The pellet was further resuspended in 0.5 ml of 
isolation buffer containing 1mM EGTA and placed in a nitrogen cell disruption 
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chamber for 10 min at a pressure of 1200 psi (Brown et al., 2004). Application of 
nitrogen cell disruption to the pellet released trapped mitochondria from 
synaptosomes due to high pressure. The suspension was then placed on top of a 
ficoll density gradient (7.5% ficoll was layered over 10.0% ficoll solution) and 
centrifuged at 100,000g for 30 min using a Beckman ultracentrifugation. The 
purified mitochondrial pellet after ficoll centrifugation was resuspended in 
isolation buffer without EGTA in an Eppendorf tube where the top ficoll layers 
were discarded. The purified mitochondrial suspension contained 
synaptoneurosomes, which was centrifuged at 10,000g for 10 minutes to give 
washing after ficoll isolation. The resulting final pellet was resuspended with 
isolation buffer without EGTA to a concentration of approximately 10 mg/ml and 
placed on ice for further assessment. 
A Clark type oxygen electrode inside a thermostatically sealed chamber 
was used to measure oxygen consumption of mitochondria in response to 
several mitochondrial substrates. The slope of the oxygen consumption was 
used to calculate mitochondria respiration rates in response to each substrate. 
To measure rate of oxygen consumption, mitochondrial protein of approximately 
200 - 300 μg/ml  was placed in respiration buffer (125 mM KCl, 2 mM MgCl2, 2.5 
mM KH2PO4, 20 mM HEPES and 0.1% BSA, pH 7.2) within the sealed 
chamber(Sullivan et al., 2004c; Sullivan et al., 2004b; Sullivan et al., 2004a). The 
mitochondrial solution was allowed to equilibrate for 1 minute and state 2 
respiration was induced by the addition of complex I substrates; 5 mM pyruvate 
and 2.5 mM malate. Two additions of 120 nmol adenosine 5’- diphosphate (ADP) 
were used to determine state III respiration followed by the determination of state 
IV respiration using 1 µM oligomycin. Mitochondrial state V respiration, which is 
the maximum electron transport, was induced by uncoupling the electron 
transport chain with 1 µM FCCP. Complex I was inhibited by 0.8 µM rotenone 
allowing the assessment of complex II driven electron transport with the addition 
of 10 mM succinate (Pandya et al., 2009). Mitochondrial function was quantified 
by measuring all the states as mentioned earlier along with the respiration control 
ratio RCR (State III oxygen consumption / State IV oxygen consumption). All 
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rates, including State III, State IV, and RCR, were calculated and compared 
using a two-way ANOVA or two-tailed unpaired t-test. 
Data Analyses  
All data sets were analyzed using Graph Pad Prism 4. To test for outliers, 
a Grubb’s test was used and outliers were removed from data sets prior to further 
analysis. Bonferroni’s post-hoc tests, if needed, were used to analyze data sets 
after either a one-way or a two-way analysis of variance (ANOVA). In all data 
sets with two groups an unpaired two-tailed Student’s t-test was used to assess 
statistical significance, which was defined as a p < 0.05 for all analyses. 
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Chapter Three: Dopamine Neuron Stimulating Peptides Dose and 
Effects in Normal Rats 
Hypothesis: DNSPs increase DA synthesis and metabolism in the nigrostriatal 
pathway of young adult F344 rats. 
Introduction 
DNSPs are novel molecules theorized to be formed from the proprotein 
form of GDNF. The amino acid sequence illustrates a large degree of sequence 
homology across multiple species (rat, mouse, human) making it likely that the 
DNSPs have biological activity (Chapter 1). Immonen et al. demonstrated DNSP-
11 has a high degree of sequence homology with neuropeptide Y and provided 
evidence of a biological effect on the excitatory post-synaptic potentials in 
hippocampal brain slices (Immonen et al., 2008). Multiple trophic factors such as 
BDNF and NGF also have biological activity of their prodomains (Lee et al., 
2001).  
The parent molecule of the three DNSPs, GDNF, is a trophic factor that 
has previously demonstrated a profound effect on the rat dopaminergic system, 
specifically the nigrostriatal pathway. GDNF delivered to the SN of 3-6 month old 
F344 rats modulates striatum neurochemistry. 28 days after delivery of GDNF 
microdialysis neurochemical measures applied within the striatum showed 
increased basal concentrations of DOPAC and HVA, potassium-evoked DA 
release, and d-amphetamine-evoked DA release. Neurochemical changes 
associated with GDNF treatment translate to increases in motor movement 
(Hebert et al., 1996).  
Because GDNF is the progenitor molecule of the DNSPs, we 
hypothesized that the DNSPs would increase DA levels and / or increase DA 
release and / or metabolism within the nigrostriatal pathway. If the DNSPs could 
provide modulatory effects similar to GDNF and minimize the negative aspects 
associated with GDNF discussed in Chapter 1, they could provide the basis for 
DA therapeutic molecules, but until the studies described in this chapter were 
performed, the DNSPs had not been tested in vivo. Before we could begin 
thoroughly testing our hypothesis, a dose response study was needed. GDNF’s 
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dosing range varies between 10 µg and 100 µg per injection depending on the 
route of administration and animal model being tested (Hoffer et al., 1994; Cass 
et al., 2000; Fox et al., 2001; Kirik et al., 2001). Therefore, DNSPs were 
administered in a similar dosing range to determine if an effect on DA neuron 
function was produced by the DNSPs.  
The site of DNSP delivery was also a concern because, in the past, GDNF 
has been delivered to multiple brain areas; striatum, SN, and ventricles. 
Significant side effects and a lack of penetrance have been demonstrated with 
intraventricular delivery of GDNF (Lapchak et al., 1998; Kordower et al., 1999). 
GDNF is normally expressed in low levels in the striatum and when exogenously 
applied to the striatum is retrogradely transported to the nigral cell bodies 
(Stromberg et al., 1993; Tomac et al., 1995a). GDNF was previously 
demonstrated to increase DA and DA metabolism in young adult F344 rats when 
delivered to the SN consequently we used a similar delivery paradigm (Hebert et 
al., 1996). In previous studies with GDNF, the entirety of the nigrostriatal pathway 
was considered and therefore delivery occurred at the cell bodies and the 
primary endpoint focused on the striatal projections. In most DA release 
paradigms of the nigrostriatal pathway, the terminal fields in the striatum are 
considered the primary site of DA release. Therefore, we used striatal 
microdialysis measures of DA and DA metabolism 28 days after the infusion as 
the primary endpoint measure to ensure detection of neurochemical changes 
similar to those seen initially with GDNF.  
A dose response was performed using a mixture of the DNSPs, but we 
began infusing rats with a single DNSP to minimize the number of variables in 
our experimental design and enhance our ability to interpret the experimental 
results. Effects from the DNSP mixture would prove difficult to elucidate because 
of the complexity of multiple drug interactions. Our understanding of the 
endogenous release of the DNSPs was limited at the time and aspects of 
synergistic interplay between the DNSPs were unknown. We hypothesized that 
at least one of the DNSPs would be effective at increasing the basal 
concentrations of DA, DOPAC, and HVA as well as increasing evoked DA 
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release within the nigrostriatal pathway. The most effective dose, 30 µg, was 
determined from the previous study and used in delivering each peptide to the 
SN.   
After striatal microdialysis showed significant neurochemical modulation 
by DNSP-11, a behavioral testing paradigm was designed to determine if the 
neurochemical changes would provide behavioral modification. Modification of 
motor movement would be the primary goal of a potential PD therapy because 
the observed neurochemical changes would lack clinical value without 
corresponding behavioral changes. Spontaneous motor movement was used to 
assess baseline motor movements focusing on movement speed and total 
distance traveled. The assessment of spontaneous motor movement in young 
adult F344 rats lacks the sensitivity drug induced behavior can provide but offers 
a comparison of movement between treatment groups.  
 The 28 day timing between DNSP delivery and sampling was determined 
because previous GDNF studies illustrate the 28 day time course to be most 
effective (Hudson et al., 1995; Kearns et al., 1997). Applied GDNF has an 
intraparenchymal life span of approximately seven days (Tomac et al., 1995a; 
Lapchak et al., 1996). GDNF has been demonstrated to have acute effects on 
excitability by modulating K+ channels increasing excitability (Yang et al., 2001). 
DNSP-11 is not detected within the extracellular space two hours after 
exogenous application (Bradley et al., 2009 (Submitted)). The large discrepancy 
between the in vivo half-lives of GDNF and DNSP-11 and the acute stimulatory 
effect on excitability led to the hypothesis that DNSP-11 may exhibit acute effects 
on DA neurochemistry. To further corroborate DNSP-11’s potential to have acute 
effects Immonen et al. demonstrated the rat homolog of DNSP-11 acutely 
increases excitatory post-synaptic potential in hippocampal slices (Immonen et 
al., 2008). To investigate potential acute effects by DNSP-11, reverse 
microdialysis was used to allow delivery of DNSP-11 while simultaneously 
sampling the neurochemical content of the extracellular space.  
DNSPs result from the processing of the proGDNF molecule. Mature 
GDNF and the DNSPs originate from the same molecule therefore similarities in 
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target or function are likely. GDNF demonstrated great possibilities as a potential 
therapeutic for diseases effecting dopaminergic neurons, but ultimately fell short. 
The goal of these studies was to begin determining the potential of the DNSPs to 
be dopaminergic therapeutics. Using the assumption that the DNSPs and GDNF 
would share similarities in target or function these studies began the 
characterization of the effects of the DNSPs in vivo. 
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Methods 
Studies of the DNSP Mixture 
Equal mass quantities (1:1:1) of DNSP-5, DNSP-11, and DNSP-17 were 
dissolved together in pH 5 citrate buffer vehicle. Three concentrations of the 
DNSP mixture were used for delivery 10 µg/ 5 µL, 30 µg/ 5 µL, and 100 µg/ 5 µL. 
The 10 µg/ 5 µL solution contained 10 µg of DNSP-5, 10 µg of DNSP-11, and 10 
µg of DNSP-17 (1:1:1 by mass). The other two solutions were made in a similar 
manner. Erin Rutherford, Ph.D. in the lab of Greg A. Gerhardt, Ph.D. infused 3-6 
month old F344 rats with one of three concentrations of the DNSP Mixture or 
citrate buffer vehicle in a manner similar to the description provided in Chapter 2: 
Infusion Delivery of DNSPs. 28 days after infusion delivery Barry M. Joyce, Ph.D. 
in the lab of Greg A. Gerhardt, Ph.D. performed microdialysis as described in 
Chapter 2: Microdialysis (Table 3.1A). Animals were euthanized and their brains 
collected for either tissue neurochemistry or immunohistochemistry following 
methods described in Chapter 2. At the time the study was performed, I was 
assisting with the procedures and gaining technical experience. For all of the 
data generated in this study I performed all the data analyses.  
Studies of individual DNSPs 
Solutions of 30 µg/ 5 µL of DNSP-5, DNSP-11, DNSP-17, or citrate buffer 
vehicle were delivered unilaterally in a blinded manner to the SN of 3-6 month 
F344 rats. To maintain consistency in DNSP delivery between studies Erin 
Rutherford, Ph.D. in the lab of Greg A. Gerhardt, Ph.D. infused 3-6 month old 
F344 rats using a similar protocol as discussed in Chapter 2. 28 days after 
infusion treatment, microdialysis was performed in the ipsilateral striatum 
following the same protocol as described in Chapter 2 (Table 3.1B). After the 
completion of microdialysis sampling, animals were euthanized and their brains 
collected for TH immunohistochemistry. Staining focused on the DNSP-11 and 
vehicle treatment groups. 
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Table 3.1 Timeline of DNSP studies in Normal F344 Rats 
 
A) A 10 µg, 30 µg, or 100 µg mixture of the DNSPs or citrate buffer vehicle 
was infused at day 0 and 28 days later microdialysis was performed in the 
striatum. Half the animals were used for tissue neurochemistry and half for 
tyrosine hydroxylase immunohistochemistry.  
B) 30 µg of DNSP-5, DNSP-11, DNSP-17, or citrate buffer vehicle was 
infused into the SN of a normal F344 rat at day 0 and 28 days later underwent 
striatum microdialysis followed by tyrosine hydroxylase immunohistochemistry in 
animals from the vehicle treatment group and from the DNSP-11 treatment 
group.  
C) Animals were habituated to movement boxes. 30 µg of DNSP-11 was 
infused unilaterally into the SN and one week later spontaneous movement 
activity was assessed weekly for 3 weeks after the infusion.  
56 
After the completion of the above study, 3-6 month old F344 rats received 
30 µg/ 5 µL of DNSP-11 and underwent motor movement evaluation weekly for 3 
weeks (Table 3.1 C).  
Data Analyses 
All data sets were analyzed in accordance with the methods discussed in 
Chapter 2: Methods. Variability within the recovery rates of microdialysis probes 
ranged from 10 – 32 % and averaged 22.6 ± 1.3 % required data to be corrected 
using the recovery rates collected at the beginning of every experiment. 
Microdialysis data were analyzed by a two-way ANOVA with Bonferroni’s post-
hoc tests. Baseline levels were calculated from samples 2-4 and averaged for 
each group then analyzed with a one-way ANOVA. Striatal and SN tissue DA 
content was analyzed by a one-way ANOVA and immunohistochemistry 
underwent qualitative visual examination. Statistical significance was defined as 
p < 0.05. 
Acute effects of DNSP-11 
Please refer to Chapter 2 for all methods used to collect and analyze data 
related to the acute effects of DNSP-11.  
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Results 
DNSP Mixture Dose Response 
To establish an effective dosing range for the mixture of the DNSPs (1:1:1 
by weight, DNSP-5, DNSP-11, DNSP-17) striatal microdialysis studies 28 days 
after infusion delivery revealed significant increases in evoked DA release 
(Figure 3.1). A differential response to the 100 mM K+ was seen in the groups 
treated with the DNSP mixture solution (Table 3.2). D-amphetamine application 
produced changes related to DNSP mixture treatment (Table 3.2). Increased K+ 
and d-amphetamine-evoked release of DA were observed at all concentrations of 
the DNSP mixture relative to the vehicle treatment group (F(3,15)=3.878, 
p=0.0094). No significant differences were observed between DNSP mixture 
treatment concentrations in relation to evoked DA release. 
The baseline DA concentration was significantly elevated only in the 10 µg 
DNSP mixture treatment group when compared to vehicle (Table 3.2). The 100 
µg DNSP mixture treatment was significantly lower than both the 10 and 30 µg 
DNSP mixture treatments, but was not significantly lower than vehicle treatment. 
Baseline concentrations of DOPAC were consistently elevated in all groups 
treated with the DNSP mixture relative to vehicle treatment (Table 3.2). Baseline 
HVA concentrations were significantly augmented by the 10 and 30 µg DNSP 
mixture treatment groups (Table 3.2) (Figure 3.2).  
Brain tissue neurochemical content was used to gain insight into metabolic 
activity by determining turnover ratios for DA in both the striatum and SN. Brain 
tissue neurochemical content in the striatum and SN of either hemisphere was 
not significantly altered after treatment with any concentration of the DNSP 
mixture (Table 3.3). Turnover ratios relate DA concentrations to the concentration 
of its metabolites DOPAC and HVA providing insights into metabolic function. No 
significant changes in turnover for the SN (F(3, 15) = 1.17, p = 0.23) or striatum (F(3, 
15) = 1.09, p = 0.38) were observed relative to the vehicle treatment group (Figure 
3.3). 
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Figure 3.1 Microdialysis Studies of Resting and Sitmulus-Evoked DA 
Release after DNSP Mixture Treatment 
(A) DA concentration throughout striatum microdialysis 28 days after infusion 
treatment delivery showed significant increases in evoked release of DA by K+ 
(B) and d-amp (C) at all amounts of the DNSP mixture (10 µg, 30 µg, and 100 
µg) relative to vehicle when analyzed by a two-way ANOVA with Bonferroni’s 
post-hoc test (F(3,15)=3.878, p=0.0094). ** p < 0.01 (Vehicle vs. 10 µg DNSP 
Mixture), ## p < 0.01, ### p < 0.0001 (Vehicle vs. 30 µg DNSP Mixture), † p < 
0.05, ††† p < 0.0001 (Vehicle vs. 100 µg DNSP Mixture). Data Points: Mean ± 
SEM, n = 8. 
 
A 
B C 
59 
 
Table 3.2 Extracellular Levels of DA and DA Metabolites 28 days after DNSP 
Mixture Infusion into the SN 
Perfusion 
Solution, 
Fraction # 
Analyte  
Analyte Concentration (nM) 28 days after 
Infusion with DNSP Mixture: F and p-
values for 
ANOVA Citrate 
Buffer 10 µg 30 µg 100 µg 
aCSF,             
2 – 4 
DA 20.71 ± 2.25 
28.79* ± 
1.79 
24.53 ± 
2.13 
15.11 ± 
1.34 
F(3,82)=8.57,  
p < 0.0001 
DOPAC 3790.0 ± 241.0 
6072.0*** 
± 388.9 
6448.0### 
± 322.3 
6258.0††† 
± 519.9 
F(3,82)=10.1,  
p < 0.0001 
HVA 1422 ± 144.1 
2104.0* ± 
197.5 
2031.0# ± 
133.5 
1927.0 ± 
124.5 
F(3,82)=4.20,  
p < 0.0081 
100 mM 
K+, 6 DA 
474.0 ± 
70.3 
801.7** ± 
89.1 
802.9## ± 
99.56 
1092.0††† 
± 414.6 
F(3,15)=3.88, 
p=0.0094 
250 µM d-
amp, 11 DA 
535.1 ± 
55.83 
882.3** ± 
79.66 
1005.0### 
± 100.6 
809.2† ± 
181.9 
F(3,15)=3.88, 
p=0.0094 
The table contains all DA related neurochemical parameters sampled by striatal 
microdialysis. * p < 0.05, *** p < 0.0001 (Vehicle vs. 10 µg DNSP mixture), # p < 
0.05, ### p < 0.0001 (Vehicle vs. 30 µg DNSP mixture), ††† p < 0.0001 (Vehicle 
vs. 100 µg DNSP mixture). Data: Mean ± SEM, n = 8. 
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Figure 3.2 Baseline Neurochemical Concentrations after DNSP Mixture 
Treatment 
Baseline concentrations of DA, DOPAC, and HVA 28 days after infusion of the 
DNSP mixture (10 µg, 30 µg, or 100µg) or citrate buffer vehicle was delivered 
unilaterally to the SN. Each neurochemical data set was analyzed by a one-way 
ANOVA with Bonferroni’s post-hoc tests. * p < 0.05, *** p < 0.0001 (vehicle vs. 10 
µg DNSP mixture), # p < 0.05, ### p < 0.0001 (vehicle vs. 30 µg DNSP mixture), 
††† p < 0.0001 (vehicle vs. 100 µg DNSP mixture). Data Points: Mean ± SEM, n 
= 8. 
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Table 3.3 Brain Tissue Neurochemical Content after DNSP Mixture 
Delivery 
Treatment 
Brain 
Area Analyte 
Vehicle 
(ng/g) 
10 µg 
DNSPs 
(ng/g) 
30 µg 
DNSPS 
(ng/g) 
100 µg 
DNSPs 
(ng/g) 
F and p values 
for one-way 
ANOVA 
 DA 4111 ± 303.0 
4461 ± 
568.6 
3414 ± 
665.5 
6105 ± 
773.7 
F(3, 15) = 3.41,     p 
= 0.06 
Lft Str DOPAC 10782 ± 752.3 
12647 ± 
2586 
15140 ± 
2917 
12988 ± 
2116 
F(3, 15) = 0.66,     p 
= 0.54 
 HVA 444.0 ± 42.85 
404.4 ± 
43.05 
392.4 ± 
66.15 
477.6 ± 
36.34 
F(3, 15) = 0.60,     p 
= 0.65 
 DA 62.09 ± 28.98 
239.0 ± 
104.0 
96.78 ± 
16.05 
200.4 ± 
41.93 
F(3, 15) = 1.82,     p 
= 0.19 
Lft 
SN DOPAC 
189.1 ± 
98.32 
566.6 ± 
154.9 
572.6 ± 
139.7 
608.8 ± 
156.1 
F(3, 15) = 1.68,     p 
= 0.21 
 HVA 27.97 ± 11.39 
59.85 ± 
13.38 
18.38 ± 
5.917 
39.02 ± 
10.00 
F(3, 15) = 2.99,     p 
= 0.06 
 DA 4014 ± 263.1 
3832 ± 
1096 
3175 ± 
653.5 
3843 ± 
751.3 
F(3, 15) = 0.22,     p 
= 0.88 
Rt Str DOPAC 10114 ± 228.4 
10794 ± 
1920 
12979 ± 
2315 
12385 ± 
2453 
F(3, 15) = 0.75,    
p= 0.41 
 HVA 448.5 ± 40.06 
387.6 ± 
56.03 
399.6 ± 
62.84 
380.2 ± 
42.10 
F(3, 15) = 0.82,     p 
= 0.35 
 DA 35.09 ± 16.42 
90.47 ± 
22.79 
72.95 ± 
16.24 
83.19 ± 
33.26 
F(3, 15) = 0.95,     p 
= 0.44 
Rt SN DOPAC 189.1 ± 98.32 
566.6 ± 
154.9 
572.6 ± 
139.7 
608.8 ± 
156.1 
F(3,15)=0.42,  
p=1.01 
 HVA 11.95 ± 2.027 
46.87 ± 
11.14 
25.37 ± 
8.045 
34.88 ± 
7.939 
F(3, 15) = 2.90,     p 
= 0.07 
The table contains the tissue levels of DA, DOPAC, and HVA in their respective 
tissues 28 days after right SN delivery of the DNSP mixture or vehicle. The F and 
p values for the one-way ANOVAs are included on the far right portion of the 
table. Data: Mean ± SEM, n = 6. 
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Qualitative analysis of the TH positive staining revealed no changes in 
fiber density or morphology in the striatum. Both the 10 µg and 30 µg doses of 
the DNSP mixture appear to increase fiber and cell body density in the SN when 
compared to vehicle treated animals (Figure 3.4). In summary, the 10 µg DNSP 
mixture increased all microdialysis related parameters relative to the vehicle 
treatment group and potentially increased TH positive neuron density in the SN 
but was not seen to alter tissue related neurochemistry. The 30 µg dose of the 
DNSP mixture significantly increased K+- and d-amp- evoked DA release as well 
as increased baseline concentrations of DA metabolites, DOPAC and HVA, when 
compared to the vehicle. However, the 30 µg dose was not seen to significantly 
affect baseline DA concentrations or DA tissue content, but possibly increased 
TH fiber density. The 100 µg dose was the least effective in eliciting a 
neurochemical response, but still was able to increase K+- and d-amp- evoked 
DA release and baseline HVA concentrations. The 100 µg DNSP mixture was not 
seen to significantly alter baseline DA or HVA concentrations relative to the 
vehicle treatment groups and provided no discernible changes in tissue 
neurochemistry or TH immunohistochemistry.   
Effects of Individual DNSPs 
After establishing an effective dose range for the DNSP mixture on DA 
related neurochemistry, responses to individual DNSPs (Individual DNSPs 
include separate 30 µg solution of DNSP-5, DNSP-11, and DNSP-17) needed to 
be assessed. Baseline neurochemical concentrations and evoked DA release 
were monitored by striatal microdialysis 28 days after infusion with individual 
DNSPs. Baseline DA concentrations (Table 3.4) were significantly increased by 
DNSP-11 treatment. No other treatment groups displayed any significant 
changes on baseline DA concentrations. Baseline concentrations of DOPAC 
(Table 3.4) were significantly higher in the DNSP-11 treatment group relative to 
vehicle and DNSP-5 treatment groups. DNSP-11 and DNSP-17 both significantly 
increased baseline HVA (Table 3.4) concentrations when compared to DNSP-5 
or vehicle.  
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Figure 3.3 DA Turnover Ratios after DNSP Mixture Treatment 
DA, DOPAC, and HVA content of striatal and SN tissue was used to provide a 
ratio focusing on DA metabolism. The above graphs demonstrate no significant 
changes in the DA turnover ratios of the SN (F(3, 15) = 1.17, p = 0.23) or striatum 
(F(3, 15) = 1.09, p = 0.38) when analyzed by a one-way ANOVA. Data: Mean ± 
SEM, n = 6. 
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Figure 3.4 TH Immunohistochemistry of the Nigrostriatal Pathway 
after DNSP Mixture Treatment 
Representative slices stained for TH immunohistochemistry. Continued and 
explained on the next page. 
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Figure 3.4 Continued 
All DNSP mixtures were characterized as well as citrate buffer vehicle. 
Photographs A, B, D, E, G, H, J, and K were taken at 10 X magnification and C, 
F, I, and L were taken at 50 X magnification. Relative to vehicle (C), the 10 µg 
DNSP mixture (F) increased the number of SN cell bodies and the 30 µg DNSP 
mixture (I) increased fiber density within the SN. No changes were seen in the 
staining of the 100 µg treatment group. In addition, the striatum of all four groups 
was observed and determined too similar to determine any differences (n=2). 
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Table 3.4 Extracellular Levels of DA and DA Metabolites 28 days after DNSP 
Infusion into the SN 
 
Perfusion 
Solution, 
Fraction # 
Analyte 
of 
Interest 
Analyte Concentration (nM) 28 days after 
Infusion with: F and p-
values for 
ANOVA Citrate 
Buffer DNSP-5 DNSP-11 DNSP-17 
aCSF,             
2 – 4 
DA 26.00 ± 2.69 
43.10 ± 
4.17 
45.84* ± 
7.70 
41.26 ± 
3.10 
F(3,59)=2.87 
p=0.0483 
DOPAC 3555 ± 337.5 
4325 ± 
429.5 
6544** ± 
836.2 
5472 ± 
274.6 
F(3,59)=6.30 
p=0.0009 
HVA 2419 ± 250.7 
2532 ± 
355.1 
4516** ± 
501.8 
3931## ± 
249.6 
F(3,59)=8.15 
p=0.0001 
100 mM 
K+, 6 DA 
541.7 ± 
125.1 
419.4 ± 
47.75 
690.4* ± 
97.06 
685.2 ± 
60.34 
F(3,15)=9.48
p< 0.0001 
250 µM d-
amp, 11 DA 
603.5 ± 
129.1 
508.0 ± 
45.97 
772.1* ± 
103.8 
783.7## ± 
64.21 
F(3,15)=9.48 
p < 0.0001 
The table contains all DA related neurochemical parameters sampled by striatal 
microdialysis. * p < 0.05,** p < 0.01 Vehicle vs. DNSP-11, # p , 0.05 ## p , 0.01  
Vehicle vs. DNSP-17. Data: Mean ± SEM, n = 6. 
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DNSP-11 was able to increase the baseline concentrations of DA, 
DOPAC, and HVA, while DNSP-17 increased baseline HVA concentrations. 
DNSP-5 produced no effect on baseline concentrations of DA, DOPAC, or HVA 
neurochemistry in this study (Figure 3.5). 
Twenty-eight days after DNSP treatment, K+ and d-amp-stimulated DA 
release was investigated. DNSP-11 treatment increased DA release in response 
to K+ stimulation, while DNSP-5 and DNSP-17 treatment produced no significant 
changes in DA release evoked by K+ (Table 3.4). DNSP-11 and DNSP-17 both 
increased d-amp-evoked DA release when compared to the vehicle treatment 
group, but DNSP-5 lacked the ability to produce any significant changes (Table 
3.4).  
A qualitative analysis of immunohistochemical staining was performed to 
reveal potential differences between DNSP-11 and vehicle treatment. Though a 
relatively small n of two hinders any definitive conclusions there is the possibility 
for more intense staining in the striatum and an increased number of 
dopaminergic fibers in the SN of the DNSP-11 treatment group (Figure 3.7).  
In summary DNSP-5 was not seen to alter any of the measured 
parameters and DNSP-17 only altered baseline HVA and d-amp-evoked DA 
release. DNSP-11 produced the most robust effects on DA-related 
neurochemical parameters: increasing evoked DA release with K+ and d-amp, as 
well as increasing baseline concentrations of DA, DOPAC, and HVA. DNSP-11 
demonstrated a potential impact on TH-positive neurons and because of the 
robust neurochemical effects; behavioral consequences to DNSP-11 treatment 
were examined. 
To measure possible behavioral changes associated with DNSP-11 
treatment, movement speed and distance traveled were determined weekly for 3 
weeks after unilateral SN administration of DNSP-11 or vehicle. Analysis of total 
distance traveled (F(1,70) = 2.734, p = 0.1027) showed no significant alterations 
between the DNSP-11 treatment groups (Table 3.5 and Figure 3.8). Movement 
speed (F(1,70) = 2.652, p = 0.1079) was not significantly affected by DNSP-11  
 
68 
 
Ve
hic
le
DN
SP
-5
DN
SP
-11
DN
SP
-17
0
10
20
30
40
50
60
*
[D
A]
 n
M
Ve
hic
le
DN
SP
-5
DN
SP
-11
DN
SP
-17
0
2000
4000
6000
8000 **
[D
O
PA
C
] n
M
Ve
hic
le
DN
SP
-5
DN
SP
-11
DN
SP
-17
0
2000
4000
6000
**
#
[H
VA
] n
M
 
Figure 3.5 Microdialysis Measures of Baseline DA and Metabolite 
Concentrations 28 Days after DNSP Infusion Treatment 
Baseline microdialysis concentrations of DA (F(3,59)=2.873 , p=0.0483), DOPAC 
(F(3,59)=6.301 , p=0.0009), and HVA (F(3,59)=8.153 , p=0.0001) after treatment with 
vehicle, DNSP-5, DNSP-11, or DNSP-17 analyzed by a one-way ANOVA with 
Bonferroni’s post-hoc tests. * p < 0.05,** p < 0.01 Vehicle vs. DNSP-11, # p , 
0.05 Vehicle vs. DNSP-17. Data: Mean ± SEM, n = 6. 
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Figure 3.6 Microdialysis Studies of Resting and Sitmulus-Evoked DA 
Release after Individual DNSP Treatment 
Extracellular levels of DA, 28 days after unilateral SN treatment with 30 μg of 
DNSP-5, DNSP-11, DNSP-17, or vehicle. Significant increases were observed 
from K+-evoked DA release after DNSP-11 treatment and from d-amp-evoked 
release after DNSP-11 and DNSP-17 treatment F(3,59)=2.873 , p=0.0483). 
Analyzed using a two-way ANOVA with Bonferroni’s post-hoc tests * p < 0.05 
vehicle vs. DNSP-11, ## p < 0.01 vehicle vs. DNSP-17. Mean ± SEM, n = 6. 
A 
B C 
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Figure 3.7 TH Immunohistochemistry after DNSP-11 or Vehicle Treatment 
Representative TH immunohistochemistry of the striatum and SN 28 days after 
DNSP-11 or vehicle treatment. Pictures A, B, D, and E are all at 10 X 
magnification. Pictures C and F are at 50 X magnification. The DNSP-11 treated 
striatum (D) showed more intense staining and the DNSP-11 treated SN (F) 
exhibits thicker dendritic arborization (n=2).  
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Table 3.5 Total Distance Traveled after DNSP-11 Treatment 
The total distance traveled of habituated normal F344 rats was determined by 
using movement boxes and no significant difference was observed after DNSP-
11 treatment relative to the vehicle treatment group. 
 Distance Traveled (cm) 
 Vehicle Treatment Group DNSP-11 Treatment Group 
Week 1 2335.13 ± 331.33 3234.38 ± 409.96 
Week 2 2291.63 ± 227.13 2905.75 ± 388.99 
Week 3 2201.13 ± 445.11 1931.62 ± 373.82 
Week 4 1704.13 ± 405.51 2090.37 ± 432.60 
Week 5 1754.50 ± 164.35 2031.50 ± 364.85 
F and p values for Two-
Way ANOVA F(1,70) = 2.734, p = 0.1027 
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treatment relative to vehicle treatment (Table 3.6 and Figure 3.8). Unilateral 
administration of DNSP-11 produced significant neurochemical increases, but did 
not appear to alter immunohistochemical staining or behavior in normal F344 
rats. 
Acute effects of DNSP-11 
DNSP-11 was delivered acutely within the striatum through reverse 
microdialysis after a baseline neurochemical concentration was collected with 
aCSF (Figure 3.9). Two-way ANOVA analysis of microdialysis recordings of DA 
(F(6, 395) = 26.26, p < 0.0001), DOPAC (F(6, 395) = 10.76, p < 0.0001), and HVA 
(F(6, 395) = 5.45, p < 0.0001) showed significant differences, but Bonferroni’s post-
hoc tests determined the only significant neurochemical change occurred in the 
DA concentration. DA was significantly increased with the application of 1 mM 
DNSP-11 (Sample 5: 46.09 ± 15.98 nM, Sample 6: 44.01 ± 13.62 nM, Sample 7: 
38.63 ± 9.72 nM, Sample 8: 35.87 ± 8.24 nM) in aCSF from samples 5 – 8 when 
compared to the same sample numbers while applying aCSF (Sample 5: 13.84 ± 
2.056 nM, Sample 6: 13.09 ± 1.82 nM, Sample 7: 11.83 ± 1.90 nM, Sample 8: 
11.97 ± 2.18 nM). Extracellular DA was increased by 1 mM DNSP-11, but 
produced no significant effects on DOPAC or HVA. Reverse microdialysis 
delivery of DNSP-11 in concentrations ranging from 3 – 300 μM produced no 
acute alterations in DA or DA related metabolites. 
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Table 3.6 Movement Speed after DNSP-11 Treatment 
Movement speed was calculated from the movement time and distance traveled 
data collected by movement boxes. DNSP-11 treatment produced no observable 
effect on movement speed in the normal F344 rats. Data: Mean ± SEM, n = 8. 
 
 
 Movement Speed (cm/sec) 
 Vehicle Treatment Group DNSP-11 Treatment Group 
Week 1 7.760 ± 0.216 7.678 ± 0.111 
Week 2 7.772 ± 0.297 7.664 ± 0.240 
Week 3 7.782 ± 0.161 7.543 ± 0.302 
Week 4 7.830 ± 0.185 7.481 ± 0.185 
Week 5 8.020 ± 0.424 7.519 ± 0.216 
F and p values for Two-
Way ANOVA F(1,70) = 2.652, p = 0.1079 
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Figure 3.8 Spontaneous Movement after DNSP-11 Treatment 
Spontaneous motor movement assessed weekly after unilateral DNSP-11 
treatment illustrated no significant behavioral changes in movement speed (F(1,70) 
= 2.652, p = 0.1079) or distance traveled (F(1,70) = 2.734, p = 0.1027)   when 
analyzed by a two-way ANOVA. Data: Mean ± SEM, n = 8.  
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Figure 3.9 Microdialysis Measures of DA, DOPAC, and HVA during 
Acute DNSP-11 Delivery 
DNSP-11 was delivered to the striatum by reverse microdialysis with the 
following concentrations: 3 μM, 10 μM, 30 μM, 100 μM, 300 μM, 1 mM. DA, 
DOPAC, and HVA values were analyzed with a two-way ANOVA with 
Bonferroni’s post-hoc tests. Acute treatment with 1 mM DNSP-11 produced 
significant increases in DA. (DA: F(6, 395) = 26.26, p < 0.0001, DOPAC: F(6, 395) = 
10.76, p < 0.0001, HVA F(6, 395) = 5.45, p < 0.0001) *** p < 0.0001 with 
Bonferroni’s post-hoc test 1mM DNSP-11 vs. aCSF. Data: Mean ± SEM, n = 8. 
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Discussion 
DNSPs Enhance Dopaminergic Function 
Enhancement of DA neurochemical function was observed in the studies 
using the DNSP mixture. All doses of the DNSP mixture were seen to increase 
the function of the normal dopaminergic system. Increased DA release in 
response to a high K+ solution was observed from all three concentrations of the 
DNSP mixture. The enhanced evoked DA response relative to the vehicle 
treatment group showed the DNSP mixture’s ability to modulate DA release, 
possibly through the manipulation of vesicle packaging, vesicle number, or 
vesicle binding. The most probable mechanism for increased evoked DA release 
would be to increase DA synthesis, which would thereby increase the availability 
of DA for packaging. GDNF increases the vesicle content of DA through 
enhanced synthesis and the DNSP mixture could use a similar mechanism to 
enhance DA release (Pothos et al., 1998).  
Increased availability of DA in the cytosol for packaging could potentially 
explain changes in d-amp-evoked DA release. A d-amp solution was delivered 
via reverse microdialysis that causes a reversal of the dopamine transporter and 
release of cytosolic DA to the extracellular space where it is then collected. The 
enhanced DA release response to d-amp elicited by the DNSP mixture treatment 
could be attributed to an increase in cytosolically available DA. Elevated cytosolic 
DA in conjunction with increased K+ evoked DA release established increases in 
DA synthesis as the most probable mechanism. 
All concentrations of the DNSP mixture increased baseline concentrations 
of DA metabolites. Modulation of the metabolites is most likely related to a 
change in DA synthesis. Enhanced DA synthesis has the potential to cause the 
increase in DA metabolites demonstrated within this study. Increasing cytosolic 
DA would augment the availability of DA to metabolic enzymes thereby 
escalating the concentration of metabolites produced. Higher DA baseline 
concentrations caused by 10 μg DNSP mixture would increase DA available for 
metabloism. Baseline DA concentrations are primarily a measure of tonic DA 
release, which is generally modified by reducing reuptake by the DA transporter 
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or modulating spontaneous DA release events. Changes in the DAT are unlikely 
because ongoing studies in our laboratory have revealed no change in reuptake 
mechanisms after DNSP treatment (Unpublished data, Meagan Littrell). To 
increase basal output without manipulating reuptake, the dopaminergic neuron 
would have to increase the frequency or concentration of spontaneous DA 
release (Goto et al., 2007).  Acute DNSP delivery studies demonstrate an 
increase in the excitatory post-synaptic potential , as well as an increase in the 
frequency of action potentials (Immonen et al., 2008). Acute post-synaptic 
changes could be related to presynaptic modifications of the concentration and 
frequency of tonic DA release that could potentiate into long-term modulation of 
tonic DA. Elevated extracellular DA levels could be related to long-term 
alterations in the concentration and frequency of tonic DA firing. 
Striatal and SN tissue content of DA, DOPAC, or HVA were unchanged 
after DNSP mixture treatment. The lack of significant tissue neurochemical data 
is surprising because of the apparent changes in DA synthesis measured by 
microdialysis. Much of the data has a high degree of variability likely related to 
multiple factors such as damage from the microdialysis probe upon removal, 
variability in the dissections, and too low of an n. Variability in tissue 
neurochemical measures resulted in variability of metabolic turnover ratios. This 
variability in the neurochemical measures eliminated any significance that could 
have been demonstrated by both the tissue content and the turnover ratios. 
Immunohistochemical staining showed no visible distinctions between the 
striatum of any treatment group. A lack of distinguishable differences in TH 
staining could be related to a lack of effect on the number of TH staining neurons 
or the effect was not robust enough to overcome the variability within an intact 
striatum. However, the SN of both the 10 µg DNSP mixture and 30 µg DNSP 
mixtures demonstrate potential enhancement in cell bodies and fiber outgrowth 
respectively. GDNF enhanced TH positive fiber outgrowth in multiple models of 
dopaminergic dysfunction and the DNSP mixture has the potential to similarly 
increase neuronal sprouting (Ebendal et al., 1995; Ai et al., 2003). Normal young 
adult F344 rats are an impractical model to visualize TH staining related effects 
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because the animal maintains an intact nigrostriatal pathway leading to a large 
number of dopaminergic fibers and less sensitivity. The lack of sensitivity of TH 
staining in the normal F344 rat can be solved in future studies by using models 
with dopaminergic cell loss to minimize the variability of the pathway before 
DNSP treatment. 
GDNF and the DNSPs have similar effects on K+ and d-amp evoked DA 
release, which in GDNF’s case was related to changes in DA synthesis due to 
modification of TH phosphorylation (Salvatore et al., 2004). Changes in evoked 
DA release and baseline metabolite concentrations are comparable to previous 
work with GDNF but do not explain the increases in baseline DA exhibited at the 
10 μg DNSP dose. Increases in DA synthesis with GDNF did not increase 
baseline DA in the normal young adult rat (Hebert et al., 1996). The DNSP 
mixture mimics functional aspects of GDNF but has additional functional 
alterations such as the increased baseline DA concentrations. Therefore, DNSP 
related functional changes are potentially mediated through multiple mechanisms 
one of which could be the same as GDNF. The DNSP mixture’s effects could 
also be mediated through an entirely different mechanism than GDNF, but with 
overlap between their signaling cascades.  
Mechanistic aspects of the DNSPs would have been difficult to elucidate 
using the DNSP mixture because of potential interactions between the three 
peptides. DNSPs could modify different aspects of dopaminergic function or they 
could act in a synergistic manner to increase activity and functional changes. 
Therefore, the next phase in our studies of the DNSPs was to determine the 
effects from the individual peptides on dopaminergic function. The 10 μg and 30 
μg dose both demonstrated effects on evoked DA release and baseline 
metabolite concentrations, but the 10 μg DNSP mixture dose was the only dose 
that exhibited the ability to modify baseline concentrations of DA. As a result of 
the DNSPs synergistic effects in cell culture, we decided to use a 30 μg dose of 
the individual DNSPs in further studies (Unpublished Data, Bradley Lab).  
In summary, the DNSP mixture increased DA synthesis and in turn 
augmented DA metabolism. Potential changes in TH positive fiber density by two 
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different DNSP mixture doses demonstrated possible modifications of 
dopaminergic neuron numbers and morphology. The tissue neurochemistry 
showed no significant effects likely due to a small n combined with a high degree 
of variability. Therefore, these studies provided a potential dose range for future 
studies and more importantly demonstrated similar effects between DNSPs and 
GDNF on nigrostriatal dopaminergic neurons.  
DNSP-11 Enhances Neuronal Function 
Neurochemical changes 28 days after treatment with 30 μg of a single 
DNSP was assessed in normal F344 rats. DNSP- 5 alone did not alter DA related 
neurochemistry as measured by microdialysis, but DNSP-17 treatment enhanced 
d-amp-evoked DA release and it increased baseline HVA. DNSP-17 potentially 
alters synthesis causing changes in cytosolic and extracellular DA. Although 
unlikely, another potential mechanism could be that DNSP-17 interacts with the 
DAT. Modifications of DAT function could increase extracellular DA for 
metabolism to HVA and simultaneously increase sensitivity to d-amp evoked DA 
release (Sulzer et al., 1993).  
DNSP-11 was the only DNSP to exhibit significant changes on all DA 
related neurochemical parameters. Effects on DA neurochemistry are similar 
between the 30 μg DNSP-11 dose and the 10 μg DNSP mixture dose. 
Neurochemical effects by DNSP-11 can be most easily explained by a 
modulation in DA synthesis (significantly increased K+ and d-amp evoked DA 
release), which would lead to corresponding alterations in DA metabolism 
(increased baseline DOPAC and HVA). DNSP-11, alone, produced the 
distinguishing feature of augmented baseline DA by modulating tonic DA release. 
The 30 μg dose of DNSP-11 provided the same modifications of the nigrostriatal 
dopaminergic pathways as the DNSP mixture.  
DNSP-11 potentially enhances TH fiber density in the SN and striatum. 
The large number of TH positive fibers in the young adult F344 rats can cause 
dfficulties interpreting the TH immunohistochemical staining. Changes in the 
number of TH positive fibers were not readily discernible because of variability 
within each group. GDNF previously exhibited robust enhancement of fiber 
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density in the SN even after neurotoxic insult (Stromberg et al., 1993; Tomac et 
al., 1995b; Grondin et al., 2002). Therefore, DNSP-11 may mimic more than just 
GDNF’s neurochemical effects. DNSP-11 may enhance fiber density and 
outgrowth similar to previous results with GDNF. Although the possibility remains 
that DNSP-11 does not affect TH positive neuron number or outgrowth, 
qualitative investigation showed a potential increase in fiber density in both the 
SN and striatum. DNSP-11 potentially altered TH staining and significantly 
enhanced DA synthesis and metabolism in a manner similar to GDNF. Evidence 
of increased TH fiber number adds to the possibility that DNSP-11’s 
neurochemical effects could be related to neuron number as well as increases in 
synthesis and metabolism. Enhancement of the DA baseline concentration was 
not previously reported with GDNF, which was able to increase TH fiber density. 
DSNP-11 increased baseline concentrations of DA distinguishing its effect from 
those of GDNF. Therefore, DNSP-11 enhances dopaminergic function with 
possible increases in DA fiber density. DNSP-11 mediated increases in DA 
neurochemistry directed future work to focus primarily on DNSP-11 and its ability 
to modulate DA neurochemistry.  
To determine if the neurochemical changes provided by DNSP-11 could 
modify motor movement we examined locomotor function after DNSP-11 
treatment. DNSP-11 did not alter measures of total distance traveled or 
movement speed at weeks 1-3 after unilateral DNSP-11 treatment. GDNF was 
previously seen to modify spontaneous motor movement parameters at 1 and 3 
weeks after infusion (Hebert et al., 1996). The lack of significant effect of DNSP-
11 treatment on behavior may stem from the lack of sensitivity of the 
spontaneous movement test due to unilateral treatment of the animals and 
bilateral behavioral endpoints. Neurochemical effects of unilaterally delivered 
DNSP-11 may not be strong enough to alter bilateral motor movement. 
In summary, the 30 μg doses of DNSP-5 and DNSP-17 were not as 
effective in altering DA neurochemistry as DNSP-11, but individual dose 
responses would need to be carried out before ruling them ineffective in 
modulating neurochemistry. Synergistic effects of the DNSPs are possible. 
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Therefore, future studies aimed at enhancing the potency or maximum effect 
need to be determined before DNSP-5 and DNSP-17 can be declared 
nonfunctional. However, future studies of DNSP-5 and DNSP-17 are beyond the 
scope of this dissertation. The 30 μg dose of DNSP-11 was effective in eliciting a 
DA neurochemical response and produced potential evidence of increases in TH 
positive neuron number. Similar to GDNF, DNSP-11 modified DA synthesis and 
metabolism 28 days after a single infusion. DNSP-11 did increase baseline levels 
of DA providing evidence of alternative mechanisms of action than GDNF. 
Acute Delivery of 1 mM DNSP-11 Induces DA Release    
DNSP-11 delivered by reverse microdialysis to the striatum significantly 
increased DA at a 1mM concentration of DNSP-11. The 1 mM DNSP-11 
perfusion solution concentration is equivalent to approximately 24 µg of DNSP-11 
delivered every 20 minutes. In using microdialysis to deliver the solution, the 
recovery rate of DNSP-11 needed to be accounted for to determine the 
concentration of DNSP-11 reaching the extracellular space. Due to detection 
limitations of DNSP-11 we were unable to accurately determine the probe 
recoveries, but summaries of probe recoveries for similar sized peptides range 
from 8 – 12% (Kehr, 1991). Assuming a 10% recovery rate, a concentration of 
approximately 100 µM DNSP-11 evoked DA release.  
The amount of DA release was similar to those previously described using 
dopamine transporter blockers, cocaine or GBR 12909 (Nomikos et al., 1990). 
DNSP-11 may block the reuptake of DA by binding the dopamine transporter 
allowing DA to build up in the extracellular space. A transporter blockade would 
have minimal effect on DA metabolites, which remain relatively stable when 
acutely treated with DNSP-11. The lack of a DA neurochemical effect at lower 
concentration is expected from a dopamine transporter blocker because of the 
large number of dopamine transporters in the dorsal striatum that must be 
overcome to cause DA to build up in the extracellular space (Cass et al., 1992). 
In summary, only the 1mM concentration of DNSP-11 increases extracellular DA 
potentially through a blockade of the dopamine transporter or an increase in the 
K+ channel sensitivity. 
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Chapter Summary 
In the studies discussed in this chapter, the DNSP mixture was 
determined to be effective in increasing DA synthesis, metabolism, and tonic 
release. The 10 µg and 30 µg concentrations of the DNSP mixture exhibited the 
potential to alter the number of TH neurons, but subsequent work continued to 
focus on neuronal function and therefore neurochemistry. A 30 μg DNSP dose 
was determined to be the most effective dose for use in future studies. The 30 μg 
dose of DNSP-11 was most effective in eliciting DA neurochemical increases 
when compared to DNSP-5 or DNSP-17. DNSP-11 elicited a substantial and 
lasting increase of DA synthesis, metabolism, and tonic release. Neurochemical 
changes exhibited by DNSP-11 are similar to those previously seen in normal 
F344 rats with GDNF (Table 3.7). The exception to the similarities to GDNF is 
DNSP-11’s ability to modulate tonic DA release. A difference in the DA 
neurochemical effects implies a difference in mechanism between GDNF and 
DNSP-11. In conjunction with the neurochemical modulation, potential increases 
in DA fiber density were seen after DNSP-11 treatment, but unilateral DNSP-11 
delivery was unable to produce significant changes in behavior. Visualization of 
changes in TH neuron number in normal animals was difficult because of the lack 
of sensitivity and therefore firm conclusions cannot be made from relatively few 
animals. Behavioral measures showed DNSP-11 treatment was unable to modify 
spontaneous locomotor movement. Acute DNSP-11 treatment at a high 
concentration showed the potential for promoting the release of DA possibly 
through the blockade of the dopamine transporter. DNSP-11 increased DA 
synthesis, metabolism, tonic release, and acutely increased extracellular DA all 
within the normal F344 rat. In addition to the effect on neurochemistry, DNSP-11 
potentially enhances DA neuron fiber density. Neurochemical modulation of the 
magnitude demonstrated by DNSP-11 is rare and in conjunction with potential 
alterations of DA neuron outgrowth could establish a basis for future 
therapeutics. Therefore, subsequent studies discussed in this dissertation will 
focus on the exploration of the limitations of DNSP-11’s effects by using varying 
models of dopaminergic dysfunction.       
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Table 3.7 Comparison of the Effects of DNSPs and GDNF on the 
Nigrostriatal Pathway of Normal F344 rats 
 
Comparison of the effects of DNSP-5, DNSP-11, DNSP-17, and previous studies 
of GDNF. Similarities between the effects of DNSP-11 and GDNF can be seen, 
with GDNF having a larger magnitude effect on evoked DA release and DNSP-
11 affecting baseline DA levels. 
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Chapter Four: DNSP-11 induced Functional Recovery in the Aged Rat 
Hypothesis: DNSP-11 will enhance or restore dopaminergic neuron 
function in the aged rat  
Introduction 
The previous chapter illustrated DNSP-11’s ability to enhance DA 
synthesis and metabolism in the normal F344 rat. To begin to understand DNSP-
11’s potential as a therapeutic molecule, its action in a model of dopaminergic 
dysfunction must be characterized. Aged F344 rats provide a relevant model of 
dopaminergic dysfunction. The aged rat has a small percentage of cellular loss 
(<30%) but high degree of dopaminergic dysfunction with deficits in DA release, 
uptake, and synthesis (Fearnley and Lees, 1991; Hebert and Gerhardt, 1997, 
1999). Alterations in DA release and uptake coincide with reductions in motor 
movement (Yurek et al., 1998). The aged rat is a model of dopaminergic 
dysfunction in which a high degree of neurons are alive but dysfunctional. 
Therefore, DNSP-11 could interact with a large degree of dysfunctional neurons 
with a goal of restoring their dopaminergic neurochemical function. Aged rats 
exhibit a continual progression of dopaminergic dysfunction providing a model to 
test DNSP-11’s potential restorative properties. As an intervention strategy, 
DNSP-11 needed to improve the function of the nigrostriatal pathway. Normal 
aging exhibits many of the continually progressing deficits and dysfunctions 
associated with PD (Fearnley and Lees, 1991).  
Analogous to PD and other models of dopaminergic dysfunction, aging 
induces behavior and motor movement deficits. By 18 months of age and 
continuing throughout their remaining life span, F344 rats have reduced motor 
activity to 70 – 80% of young adult (3-6 month) motor activity (Lapchak et al., 
1997; Hebert and Gerhardt, 1998). The decline in motor movement is unlikely 
associated with changes in DA content, which is a point of contention in the field 
reduced by approximately 0 - 30 % in rodents at 22 months of age (Morgan et al., 
1987; Stanford and Gerhardt, 2001; Rollo, 2009). The possible reduction in 
content could be related to changes in synthesis, explained by the 55% reduction 
in TH activity due to increased oxidative inactivation (De La Cruz et al., 1996). A 
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decline in TH activity could reduce DA synthesis and thereby reduce content 
however; the changes in DA content alone are not large enough to induce the 
reported motor deficits. In PD, a reduction in the DA content is thought to be in 
the 60 – 80% range before motor impairment can be visualized (Braak et al., 
2004; Rollo, 2009). Further investigation of the age related dopaminergic 
dysfunction found a decreased capacity for release and uptake of DA. The 
reduced dopamine transporter function is related to the decline in plasma 
membrane expression of DAT (Hebert and Gerhardt, 1999; Salvatore et al., 
2003). Changes in DA content, synthesis, and uptake regulation seen in aged 
rats provides a uniquely challenging system with multiple components of normal 
dopaminergic function yet still exhibiting dysregulation.  
Many of the age-related deficits of the nigrostriatal dopaminergic system 
have been related to mitochondrial dysfunction due to mitochondrial DNA 
damage over time (Reeve et al., 2008). The increased bioenergetic burden of 
dopaminergic neurons within the nigrostriatal pathway increases susceptibility to 
age-related mitochondrial DNA damage that leads to dysfunction and increased 
production of reactive oxygen species (Banerjee et al., 2009). Reactive oxygen 
species further damage the mitochondrial membranes and induce apoptosis of 
dopaminergic neurons (Arthur et al., 2009). Dopaminergic neuron loss in the SN 
has been approximated at 36% in humans over the age of 85 and a portion has 
been attributed to apoptosis due to increases in reactive oxygen species (Rudow 
et al., 2008). GDNF reduces the concentration of reactive oxygen species, which 
could reduce apoptosis of dopaminergic neurons  (Smith and Cass, 2007). The 
GDNF-induced reduction in reactive oxygen species coincides with increased 
neuroprotection from reactive oxygen species generating neurotoxins, 6-OHDA, 
in aged animals (Fox et al., 2001). GDNF’s neuroprotective properties could be 
related to the inhibition of mitochondrial induced apoptosis or an overall 
modulation of mitochondrial function (Mograbi et al., 2001). Therefore, efficiency 
of mitochondrial function in the aged animal was compared using mitochondrial 
respiration rates of vehicle and DNSP-11 treatment groups.  
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GDNF bilaterally increases basal extracellular DA, motor movement, and 
unilaterally enhances K+ and d-amp evoked DA release in the aged nonhuman 
primate (Grondin et al., 2003b). In the aged rat, GDNF treatment increases 
spontaneous movement parameters, total distance traveled and movement 
speed, 3 weeks after treatment. Striatal baseline concentrations of DA, DOPAC, 
HVA, and evoked DA release (K+ or d-amp) were elevated in the aged rat 28 
days after GDNF treatment. GDNF treatment also increased SN tissue content of 
DA, DOPAC, and HVA in the aged rat (Hebert and Gerhardt, 1997). Many of the 
neurochemical changes are likely related to changes in dopaminergic synthesis 
caused by the increased content of phosphorylated TH after GDNF treatment 
(Salvatore et al., 2004). The enhancement of TH function by GDNF alleviates 
some of the strain put on the system by the age induced oxidative damage to 
active TH. Neurochemical parameters are modified by GDNF in the aged animal 
and tonic release is increased by enhancing the firing rate of movement related 
neurons (Stanford et al., 2007). GDNF enhances neurochemical and 
electrophysiological function of nigrostriatal dopaminergic neurons in the aged 
rat. 
Dopaminergic dysfunction  in the aged animal provides a test bed to 
determine the ability of DNSP-11 to intervene and restore a dysfunctional 
dopaminergic system. The aged rat models dopaminergic dysfunction, and 
DNSP-11 can act upon the large number of surviving neurons. Positive results in 
the aged rat can provide further validation of DNSP-11 as the basis for 
dopaminergic therapeutics. I hypothesize DNSP-11 will improve dopaminergic 
neurochemical function and increase mitochondrial function.  
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Methods 
Bilateral Infusion of DNSP-11 or Vehicle into the SN 
Aged (24-month-old) Fischer 344 rats were treated with DNSP-11 or 
citrate buffer vehicle delivered bilaterally to the SN. The individual performing the 
infusion was blinded to the treatment the animals received. A total of 30 µg/5µL 
of DNSP-11 was delivered to the aged rat’s SN at a rate of 0.25 µL/min. A similar 
protocol was followed as discussed in Chapter 2, and the same coordinates were 
used to treat two SN points within each hemisphere. 
Bilateral Microdialysis Studies 
Twenty-seven days after infusion treatment, bilateral microdialysis was 
performed under isoflurane anesthesia. Bilateral microdialysis uses a 
microdialysis probe placed in the striatum of each hemisphere to determine the 
extracellular neurotransmitter concentrations in both hemispheres of an aged rat. 
A CMA 11 probe with a 2 mm probe length was used to deliver and sample fluid 
to and from the dorsal striatum using the following stereotaxic coordinates; (TB: -
2.3 mm, AP: +1.5 mm,  ML: +2.3 mm, DV: -6.0 mm). The bilateral microdialysis 
technique used the same methodology as describe in Chapter 2 for probe 
recoveries, solution delivery, and sample collection. Animals were allowed to 
recover for two days after microdialysis to allow clearance of the anesthesia 
before euthanizing and harvesting tissue for mitochondrial, neurochemical, and 
TH immunohistochemical studies (Table 4.1). 
Euthanasia and Tissue Dissection 
Two days after bilateral microdialysis, animals were euthanized with CO2 
asphyxiation and the brain sectioned into quadrants. The striatum was removed 
from both anterior quadrants of the brain; one of which was used to assess 
mitochondrial respiration and the other for neurochemical analysis. The SN from 
one posterior quadrant was removed for analysis of mRNA contingent upon 
positive neurochemical or mitochondrial results. The remaining brain quadrant 
was post-fixed for immunohistochemical staining. For more details on the  
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Table 4.1 Study Design for determining DNSP-11’s Restorative 
Effects in Aged F344 rats 
DAY 0 Bilateral Infusion (n = 10) 
DAY 27 Bilateral Microdialysis 
DAY 29 
CO2 Euthanasia and Dissection 
SN - mRNA Analysis (Canceled) 
SN - TH Immunohistochemistry 
striatum - Tissue Neurochemistry 
striatum - Mitochondrial Respiration 
To determine DNSP-11’s effects in aged F344 rats, vehicle or DNSP-11 was 
infused bilaterally into the SN. Twenty-seven days later, bilateral microdialysis 
was performed under isoflurane anesthesia to determine neurochemical effects 
of DNSP-11. Animals were allowed to recover from isoflurane anesthesia for two 
days and then euthanized with CO2.  
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methodology used for the assessment of TH staining, tissue neurochemical 
content, and mitochondrial respiration please refer to Chapter 2. 
Data Analyses 
Microdialysis data were not corrected for probe recoveries because all 
microdialysis probes were prescreened before use and only used if the 
recoveries were in the range of  12 -18% (Probe recovery Averaged 16 ± 0.5 %, 
n=12). Microdialysis data collected from each hemisphere were treated 
independently and analyzed by a two-way ANOVA with Bonferroni’s post-hoc 
tests. Baseline neurochemical concentrations were determined from samples 2 
through 4 for each animal and analyzed with an unpaired two-tailed Student’s t-
test. Tissue neurochemistry and mitochondrial respiration data was analyzed by 
a two-tailed Student’s t-test comparing DNSP-11 and vehicle treatment groups. 
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Results 
Microdialysis Measured Baseline and Evoked DA Concentrations 
Bilateral microdialysis was performed 27 days after bilateral DNSP-11 or 
vehicle infusion. DA release was evoked using 100 mM K+ and 250 μM d-amp 
(Table 4.2 and Figure 4.1). DNSP-11 treatment (F(1,16) = 4.02, p = 0.0454) 
significantly reduced K+-evoked DA release but did not alter d-amp-evoked DA 
release. Baseline DA, DOPAC, and HVA concentrations were calculated from 
microdialysis samples 2-4 (Table 4.2). DNSP-11 treatment significantly 
decreased baseline concentrations of DA and DOPAC in aged F344 rats (Figure 
4.2).  
Striatal Tissue Neurochemical Content 
One striatum from each animal was used for HPLC-EC neurochemical 
analysis. DA, DOPAC, and HVA content were analyzed for each sample and the 
average neurochemical level for each group was analyzed by a two-tailed 
Student’s t-test (Table 4.3). No significant differences between treatment groups 
were found in the striatal tissue content of DA, DOPAC, or HVA. Neurochemical 
content was used to calculate the DA turnover ratio (DA/(DOPAC + HVA)). DA 
turnover ratios relate DA synthesis to DA metabolism, but no significant 
differences were observed between the vehicle and DNSP-11 treatment groups 
(Figure 4.3). 
Mitochondrial Respiration   
Striatal mitochondria were isolated, purified, and their oxygen 
consumption measured in reaction to multiple substrates. Substrates were used 
to isolate and test the function of specific portions of the electron transport chain. 
The RCR exemplifies the efficiency of mitochondrial function by providing a ratio 
of oxygen consumption during the production of ATP and during the blockade of 
ATP synthesis. The RCR for the vehicle treatment group was 12.03 ± 0.96 and 
the DNSP-11 treatment group was 11.33 ± 1.17. When the data was analyzed by 
a two-tailed Student’s t-test, no significant difference in RCR score was detected 
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Figure 4.1 Microdialysis Measures of Striatal Extracellular DA in the 
Aged F344 Rat 
DNSP-11 was seen to decrease resting DA levels and decreased K+-evoked DA 
release. Striatal DA concentration sampled through microdialysis 27 days after 
DNSP-11 or vehicle SN infusion. DA concentration data was analyzed by a two-
way ANOVA with Bonferroni’s post-hoc tests to compare across treatment 
groups (F(1,16) = 4.02, p = 0.0454). Significant decreases in K+ evoked DA release 
were observed after DNSP-11 treatment (**p < 0.01). Data Points: Mean ± SEM, 
n = 16. 
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Table 4.2 Extracellular Concentrations of Microdialysis Measured 
Neurochemicals 
DNSP-11 treatment significantly decreased K+ evoked DA release and baseline 
levels of DA and DOPAC. Neurochemical concentrations were collected through 
bilateral microdialysis 27 days after DNSP-11 or vehicle treatment. Baseline 
concentrations of DA, DOPAC, and HVA were analyzed by a two-tailed t-test and 
evoked DA release was analyzed by a two-way ANOVA with Bonferroni’s post-
hoc tests. (*p < 0.05, **p <0.01) Data: Mean ± SEM, n = 10. 
 
 
Perfusion 
solution 
and 
Sample # 
Neurochemical  
Analyte 
Vehicle 
Treatment 
Analyte 
Concentration 
(nM) 
DNSP-11 
Treatment 
Analyte 
Concentration 
(nM) 
t and p values 
for Student’s t-
test or 
Bonferroni’s 
post-hoc tests 
aCSF 
Samples  
2 - 4 
(Baseline) 
DA 4.62 ± 0.32 3.72 ± 0.24* t(32)= 2.19, p = 0.031 
DOPAC 903.8 ± 42.25 727.8 ± 35.03* 
t(32)= 3.16, 
p = 0.0021 
HVA 621.9 ± 33.5 562.6 ± 31.03 t(32)= 1.29, p = 0.202 
100 mM 
K+  
Sample 6 
DA 59.70 ± 8.522 43.85 ± 4.61** 
t(32)= 3.91, 
p < 0.01 
250 µM   
D-amp 
Sample 
11 
DA 87.87 ± 8.53 83.03 ± 8.59 t(32)= 1.19, p > 0.05 
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Figure 4.2 Reduction of Baseline Extracellular Neurochemical 
Concentrations of DA and DOPAC 
Baseline microdialysis concentrations were calculated from the neurochemical 
concentration in microdialysis fractions 2-4. Data were analyzed with a two-tailed 
Student’s t-test to determine differences between treatment groups. The baseline 
DA (t(32)= 2.19, p = 0.031) and DOPAC (t(32)= 3.16, p= 0.0021) concentrations 
were significantly reduced after DNSP-11 treatment relative to the vehicle 
treatment group (* p < 0.05, ** p < 0.01). The HVA (t(32)= 1.29,p = 0.202) 
concentration demonstrated no significant changes between treatment groups. 
Data: Mean ± SEM, n = 10. 
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Table 4.3 Striatal Tissue Neurochemical Content 29 days after SN 
Infusion Treatment  
Tissue 
Sample 
Neurochemical  
Analyte 
Vehicle Group 
Neurochemical 
Content (ng/g) 
DNSP-11 
Group 
Neurochemical 
Content (ng/g) 
t and p values 
for Student’s t 
test 
Intact 
Striatum 
DA 19399 ± 950.6 18086 ± 602.1 t(20)= 1.11, p = 0.28 
DOPAC 4995 ± 844.5 4623 ± 702.4 t(20)= 1.11, p = 0.28 
HVA 1553 ± 90.1 1492 ± 70.1 t(20)= 0.518, p = 0.61 
 
The striatal neurochemical content 29 days after SN delivery of DNSP-11 or 
vehicle. The striatum tissue was dissected and DA, DOPAC, and HVA 
neurochemical levels were determined from known standards. Data were 
analyzed using a two-tailed t-test with no significant differences between 
treatment groups. Data: Mean ± SEM, n = 10. 
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Figure 4.3 Striatal DA Turnover Ratios in the Aged F344 Rat following 
DNSP-11 Treatment 
The ratio of DA to its metabolites is used to represent any changes in the 
metabolism of DA. The ratio graphically represented above was not statistically 
different between treatment groups when analyzed by a two-tailed Student’s t-
test ( t(20) = 0.0801 p = 0.937). Data: Mean ± SEM, n = 10. 
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between groups (Figure 4.4). Oxygen consumption rates from all mitochondrial 
respiration states were compared between treatment groups by a two-way 
ANOVA with Bonferroni’s post-hoc tests (Data Not Shown). No significant 
difference between DNSP-11 and vehicle treatment groups was identified 
through statistical analysis. 
SN TH Immunohistochemistry 
One of the SN from each animal was harvested for TH 
immunohistochemistry to examine any qualitative changes in TH fiber density or 
morphology. Visual comparison of the TH stained SN from each treatment group 
revealed no pronounced differences in the density or morphology of the TH 
positive neurons (Figure 4.5). 
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 Figure 4.4 Striatal Mitochondrial Respiratory Control Ratio 
No differences in the mitochondrial control ratios were observed between DNSP-
11 and vehicle treatment. The mitochondrial respiratory control ratio represents 
the efficiency and function of the mitochondria in the striatum 29 days after 
DNSP-11 or vehicle treatment. Comparison of the two treatment groups was 
made using a two-tailed Student’s t-test (t(20) = 0.4695, p = 0.64). Analysis of the 
data revealed no significant difference between the treatment groups. Data: 
Mean ± SEM, n = 10. 
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Figure 4.5 TH Staining 29 days after DNSP -11 Infusion to the SN 
TH immunohistochemistry in the SN of the aged rat 29 days after DNSP-11 (C 
and D) or vehicle treatment (A and B) revealed no observable differences in TH 
positive cell body or fiber density. Photographs A and C were taken under 10 x 
magnification while B and D were under 50 x magnification (n = 10).  
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Discussion 
DNSP-11 treatment in the aged rat produced small (20-30%) significant 
decreases in microdialysis-measured striatal neurochemistry. Baseline 
concentrations of DA and DOPAC were significantly decreased by DNSP-11 
along with a significant reduction in K+-evoked DA release. Neurochemical 
changes measured in the striatal extracellular space showed potential 
modulation of synthesis, metabolism, or release. The previous chapter 
demonstrated DNSP-11’s potential to modulate DA synthesis and therefore the 
most probable explanation would be a decrease in synthesis related to the dose 
of DNSP-11. GDNF affects TH activity, through phosphorylation and at higher 
doses, reduces TH content and DA synthesis (Rosenblad et al., 2000; Salvatore 
et al., 2004). GDNF showed a bilateral effect on aged animal neurochemistry 
(Grondin et al., 2002). Therefore, bilateral dosing of DNSP-11 could modify the 
dose response range and produce a decrease in DA synthesis and a subsequent 
decline in DOPAC, the primary metabolite in the rat. A decline in DA synthesis by 
DNSP-11 would diminish baseline DA, baseline DOPAC, and K + evoked DA 
release, but DNSP-11 would also be expected to decrease d-amp evoked 
release. There was no observable difference in TH staining of the SN  between 
treatments, though not performed quantitatively, a large reduction in TH content 
caused by excessive DNSP-11 would be anticipated to be visible in the TH 
staining density. Modifications in DA synthesis were not observable in TH 
staining or d-amp-evoked DA release and striatal tissue neurochemical data 
showed no change in DA, DOPAC, or HVA. Therefore, alternative mechanisms 
for modifying baseline and evoked DA release needed to be examined.  
Brain tissue neurochemical data in conjunction with microdialysis data 
provided evidence that synthesis and metabolism of DA are unchanged after 
DNSP-11 treatment. Therefore, the release of DA must be modified to achieve 
the changes in DA and DOPAC observed by microdialysis after DNSP-11 
treatment. To reduce basal DA and DOPAC the frequency or size of release 
must be affected. In the previous chapter, DNSP-11 increased baseline DA 
possibly through increased DA synthesis (Pothos et al., 1998; Yang et al., 2001). 
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Less DA and DOPAC were observed in the extracellular space in the aged 
animals as well as decreased K+ evoked DA release, which could be related to 
decreased DA packaging. However, decreased DA packaging with no significant 
changes in synthesis should increase cytosolically available DA, which would be 
observed through d-amp-evoked DA release. Therefore, a reduction in K+ evoked 
release would not be expected unless the membrane hyperpolarization reduces 
the number of terminals recruited to release DA.  
Alterations in neurochemical function between treatment groups may be 
related to the isoflurane anesthetic interactions with functional changes related to 
DNSP-11 treatment. Isoflurane can increase baseline concentrations of DA and 
decrease evoked DA release potentially mediated through D2 autoreceptor 
interactions (Tsukada et al., 1999). Isoflurane alters the turnover ratio of DA  
through the internalization of DAT (Byas-Smith et al., 2004). Isoflurane 
modifications of the DA transporter and autoreceptor could interact with 
modifications caused by DNSP-11 to mask or reverse overall neurochemical 
effects. If DNSP-11 increased baseline DA and evoked DA release, the 
subsequent application of isoflurane could interact with the autoreceptors 
causing a down regulation of the elevated DA. Therefore, DA concentrations 
elevated by DNSP-11 treatment could be decreased below vehicle treatment 
without modifying DA synthesis.                             
Mitochondrial function was not significantly modified by DNSP-11 
treatment, which could be related to a lack of an effect on mitochondrial function. 
But cell culture data would suggest DNSP-11 can modulate susceptibility to 
mitochondrial toxins and modulate mitochondria membrane potential 
(Unpublished data, Luke Bradley). Therefore, it is possible isoflurane anesthesia 
2 days before tissue collection may have affected the mitochondrial function. 
Isoflurane depolarizes the mitochondrial membrane and the two day wash out 
period between anesthesia delivery and tissue collection may not provide a long 
enough time for those effects to dissipate (Bains et al., 2009). The depolarization 
event occurs through the reversal or uncoupling of ATP synthase and may 
reduce ATP production and create an energy shortage within the neurons 
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(Ljubkovic et al., 2007). Therefore, isoflurane-mediated modifications in 
mitochondrial function could mask the differences in mitochondrial function 
between treatment groups. 
DNSP-11 showed negative effects on DA neurochemistry in the aged 
F344 rat and may not have positive neurochemical effects in the aged animal. 
DNSP-11 may not be able to reverse the dysfunction demonstrated by the aged 
dopaminergic system in DAT localization, TH activity, or DA content. GDNF 
provides restoration of the dysfunctional dopaminergic system in the aged rat by 
enhancing tissue content and baseline concentrations of DA, DOPAC, and HVA. 
DNSP-11 decreased the DA and HVA baseline concentrations and had no effect 
on the neurochemical content of the striatum. GDNF elevates evoked DA release 
induced by K+ or d-amp and DNSP-11 decreased K+ evoked DA release without 
any effect on d-amp evoked DA release (Hebert and Gerhardt, 1997). DNSP-11 
was unable to modulate mitochondrial function and GDNF has been implicated in 
stabilizing mitochondrial function through the blockade of mitochondrial induced 
apoptosis and reduction in reactive oxygen species. 
Chapter Summary  
GDNF and DNSP-11 have contrasting effects in the aged rat (Table 4.4). 
GDNF affects almost every aspect of DA neurochemical function in the aged 
animal while DNSP-11 showed minimal effects. DNSP-11 decreased baseline 
levels of DA, baseline levels of DOPAC, and K+ evoked DA release. No effects 
were observed by DNSP-11 on mitochondrial function, TH staining, or tissue 
neurochemistry. Differences in the effects of DNSP-11 and GDNF could be 
related to modifications in the study design, specifically isoflurane anesthesia, or 
differences in the signaling and function of DNSP-11. Isoflurane modifies the 
dopaminergic system by interacting with the D2 autoreceptor and DAT, which 
could mask or reverse changes related to DNSP-11 treatment. It is unknown how 
isoflurane interacts with trophic factor like-modulation of the dopaminergic 
system and cannot be determined from these studies. 
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Table 4.4 Comparison of the Effects of DNSP-11 and GDNF in Aged 
F344 rats 
 
A comparison of the effects of DNSP-11 and previous work with GDNF shows 
drastically different effects on the aged dopaminergic system in F344 rats. GDNF 
robustly increases evoked DA release while DNSP-11 reduces K+-evoked 
release and has no effect on d-amp-evoked DA release. Both DNSP-11 and 
GDNF affect baseline concentrations of DA and DOPAC, but DNSP-11 
decreases baseline DA and DOPAC and GDNF increases baseline DA and 
DOPAC. The differential effects of DNSP-11 and GDNF show a possible 
divergence in mechanism of action between DNSP-11 and GDNF. 
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Therefore, DNSP-11 may restore the dopaminergic system but needs to be 
thoroughly tested using another anesthetic. DNSP-11 minimally modified the 
dopaminergic system of the aged F344 rat. The reduction in dopaminergic 
function is potentially related to an excessive dose of DNSP-11 or the 
anesthesia’s effects on the dopaminergic system. This study raises many 
questions related to anesthesia function, contrasting effects of GDNF and DNSP-
11, and DNSP-11 function but DNSP-11 did manage to modify neurochemistry in 
the aged rat. DNSP-11 has exhibited neurochemical effects in the normal F344 
rat and the aged F344 rat. The neurochemical changes observed in all studies 
made it necessary to continue investigation of DNSP-11’s ability to modulate the 
dopaminergic system.  
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Chapter Five: Neuroprotection and Restoration in the 6 –
Hydroxydopamine – lesioned rat by DNSP-11 
Hypothesis: DNSP-11 will provide neuroprotective and neurorestorative 
effects on dopaminergic neuron function. 
Introduction 
In Chapter 3, DNSP-11 enhanced DA neurochemistry and potentially 
increased dopaminergic neuron fiber density in normal rats. In Chapter 4, DNSP-
11 decreased DA neurochemistry in the aged rat. The neurochemical and 
potential neuropil changes associated with DNSP-11 treatment, show DNSP-11 
could provide the basis for future therapeutics against diseases affecting 
dopaminergic function. Results with DNSP-11 showed it can enhance function in 
normal rats and has the potential to restore and/or enhance the age-related 
dysfunctional dopaminergic system. A true assessment of its potential as a 
therapeutic for dopaminergic dysfunction occurs in model systems demonstrating 
a loss of function. At this time, there are two competing theories on the treatment 
of dopaminergic functional loss with trophic molecules: neurorestoration and 
neuroprotection.  
Neurorestoration is based primarily on the ability of trophic factors to 
induce neuronal sprouting and restore neuron function by modifying synthesis 
and metabolism (Lang and Obeso, 2004; Gash et al., 2007). In a 
neurorestoration paradigm, behavioral deficits are already established and the 
correlative neurochemical loss has already reached symptomatic levels. In this 
case, restoration of neuronal function needs to be achieved to enhance 
dopaminergic function and reduce behavioral symptoms. Restoration of neuronal 
function is considered a difficult task and has only been demonstrated in the 
laboratory by a few molecules (Dauer, 2007). A possibly more attainable 
intervention strategy would be to stop the progression of dopaminergic neuron 
loss. 
Neuroprotection is an intervention strategy based primarily on stopping the 
progression of dopaminergic cell and functional loss. A key to the effectiveness 
of a neuroprotection based treatment strategy is early detection (Braak et al., 
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2004).  Upon detection of a disease reducing dopaminergic function, a 
therapeutic intervention would begin to stop the continued loss of function but 
would not restore any of the preceding loss. Therefore, early detection strategies 
in conjunction with a neuroprotective agent would prevent the symptomatic 
phase of the disease but otherwise would not fully alleviate established 
neurochemical and cellular deficits. Both neuroprotection and neurorestoration 
strategies are flawed, but a combination of both neuroprotection and 
neurorestoration would be the most beneficial for alleviation of symptoms and 
subsequent progression (Olanow et al., 2003). 
In this chapter, two model systems were used in two different study 
designs to assess DNSP-11’s ability to protect and restore dopaminergic 
function. Assessment of DNSP-11’s neuroprotective properties used a model 
delivering 6-OHDA to the dopaminergic terminals in the striatum. This method 
provides consistent loss of dopaminergic function by reducing dopaminergic fiber 
numbers and dopamine content in the striatum and SN by 60 -80% (Kirik et al., 
1998). The reduction in DA content provides correlative stable behavioral deficits 
that are both drug induced and spontaneous. Behavioral changes can then be 
used to provide evidence of DA related changes in function. Both the cell loss 
and neurotransmitter loss demonstrated by this model of dopaminergic 
dysfunction correlates well with the cell loss and neurotransmitter loss 
demonstrated in early stage PD (Kirik et al., 1998).  A key to assessing 
neuroprotection with this model of dopaminergic cell loss is pretreatment with 
DNSP-11. DNSP-11 was delivered to the striatum six hours before 6-OHDA 
allowing DNSP-11 to establish its effects before being challenged by the 
neurotoxin. The goal of this study was to determine DNSP-11’s neuroprotective 
properties against neurotoxin induced cell death.  
An alternative model of dopaminergic cell loss is one that delivers 6-
OHDA to the MFB, which reduces DA function by greater than 90% (Schwarting 
and Huston, 1996). The severe loss of dopaminergic function reduces the 
baseline levels of dopaminergic function, fiber content, and behavior increasing 
sensitivity of endpoint measures to neurochemical and neuropil alterations. 
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Extreme cellular loss and subsequent loss of dopaminergic function induced by 
the MFB lesion provides a model system relevant to end stage PD (Kirik et al., 
1998). In this model, restoration of dopaminergic function is necessary to 
demonstrate any significant behavioral recovery. The dopaminergic loss is so 
severe in this model system that there are very few dopaminergic neurons for a 
therapy to target. Therefore, to induce any restoration of neurochemical or 
behavioral deficits, the therapeutic must be able to robustly modify function of a 
very limited population of neurons. DNSP-11 therapy was delivered to the SN 
after dopaminergic neuron loss had stabilized for 5 weeks providing a study 
paradigm to assess restoration. In a similar manner to previous GDNF studies, 
the dose was increased to 100 μg from the 30 μg used in normal animals. 
Behavioral and neurochemical measures of restoration were the focus of these 
studies but TH positive neuron density was also assessed. The goal of the study 
was to determine the restorative effects of DNSP-11 after neurotoxin induced 
dopaminergic cell loss. 
The neuroprotective effects of GDNF have been studied thoroughly, and 
GDNF protects against multiple neurotoxins (Kirik et al., 2000; Sawada et al., 
2000; Cass et al., 2006). GDNF requires delivery approximately 6 hours before a 
neurotoxic insult, allowing protein synthesis, and providing neuroprotection 
(Kearns and Gash, 1995; Kearns et al., 1997). The area of administration does 
modify the effectiveness of GDNF in protecting against dopaminergic neuron 
loss. When GDNF is administered into the SN and the 6-OHDA into the striatum 
there is only protection of the cell bodies and no neuroprotection of the axons. 
However, when both GDNF and 6-OHDA are delivered to the striatum, and 
GDNF is given adequate time to modulate protein synthesis, there is protection 
of both the axons and cell bodies (Kirik et al., 2000). In the design of our studies, 
adequate time was allowed for protein synthesis between DNSP-11 and 6-OHDA 
delivery, according to previous work with GDNF (Kearns and Gash, 1995; Kearns 
et al., 1997). To ensure the most robust response, both 6-OHDA and DNSP-11 
were delivered to the striatum increasing the possibility of exhibiting an effect on 
both the axons and cell bodies.  
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In multiple neurorestoration testing paradigms, GDNF has produced 
significant and lasting effects on DA neurochemistry, behavior, and fiber density 
(Tomac et al., 1995b; Grondin and Gash, 1998). In the most similar testing 
paradigms to the one discussed in this chapter, GDNF demonstrated a lasting 
reduction in  apomorphine-induced rotation behavior and increased 
neurochemical content in the SN (Hoffer et al., 1994). Reductions in drug 
induced rotation behavior began 1 week after infusion and lasted for four weeks. 
GDNF significantly increased SN DA and DOPAC content four weeks after 
treatment. GDNF increased the number of cell bodies and neurites in the SN 
(Bowenkamp et al., 1995). Similar results on DA neurochemistry, behavior, and 
neurons were hypothesized to occur with DNSP-11 treatment. 
DNSP-11 increased the function of an intact dopaminergic system and 
had similar effects to GDNF in the normal animal. In conjunction with the effects 
of DNSP-11 on the aged animal and previous work with GDNF, we hypothesized 
DNSP-11 would have both neuroprotective and neurorestorative effects. These 
two studies would reveal DNSP-11’s true potential as the basis for therapeutic 
molecules against dopaminergic dysfunction. 
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Methods 
Please refer to Chapter 2 for a detailed review of all methods used within 
this chapter.  
 DNSP-11 Restoration  
DNSP-11 or vehicle was infused to F344 rats after they had demonstrated 
a greater than 90% reduction in dopaminergic function through apomorphine 
induced rotation behavior. Rotational behavior was assessed for 4 weeks after 
treatment and striatal and SN tissue was taken 5 weeks after the infusion 
treatment. Tissue was taken primarily for neurochemical analysis, but two 
animals exhibiting representative rotational behavior from each group were used 
for TH staining (Table 5.1A). 
DNSP-11 Neuroprotection  
F344 rats were tested in a modified cylinder test to assess baseline paw 
usage for each animal. A week later, animals were treated with DNSP-11 or 
vehicle within the striatum and 6 hours later were treated with 6-OHDA to the 
same striatum coordinates. The lesion was allowed to progress for two weeks 
after which time asymmetrical paw use and amphetamine induced rotation 
behavior was assessed. Behavioral measures were monitored for 4 weeks and 
the animals were euthanized and brain tissue taken. Tissue was primarily used to 
assess changes in neurochemical content. Two animals exhibiting representative 
rotation behavior from each group were taken for TH staining (Table 5.1 B). 
Data Analyses 
Data analyses were performed using an unpaired two-tailed Student’s t-
test for all tissue neurochemical data, and behavioral data was analyzed by two-
way ANOVA with Bonferroni’s post-hoc tests. Apomorphine-induced rotational 
behavior was represented as a percentage of the vehicle for simplification and 
was analyzed by a one-way ANOVA with Bonferroni’s post-hoc tests. 
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Table 5.1 Study Design for Assessment of DNSP-11-induced 
Restoration and Neuroprotection 
 
A) The study design used to test neurorestorative effects by DNSP-11. 
After neurotoxin delivery, the dopaminergic cell loss was allowed to stabilize 
before treatment with DNSP-11. Recovery from the cell loss was the primary 
comparator between the two groups. 
B) The study design used to test neuroprotective effects produced by 
DNSP-11. Delivery of DNSP-11 preceded neurotoxin delivery and the 
progression and extent of deficit produced by the neurotoxin was the primary 
comparator between the two groups. 
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Results  
Rotational Behavior and Paw Placement in Neuroprotection Study  
Amphetamine induced rotation behavior was assessed three weeks after 
the injection of DNSP-11 or vehicle and 6-OHDA. No significant difference was 
observed between the vehicle and DNSP-11 treated groups at week 3 or any of 
the subsequent weeks that followed (F(1,22) = 0.18, p = 0.676) (Figure 5.1). 
Schallert’s cylinder test provided data differentiating paw use before and 
after 6-OHDA delivery. The data depicts hemisphere specific changes in motor 
movement and used within animal controls comparing the movement in the right 
paw (intact hemisphere) to movement in the left paw (lesioned hemisphere). 
Data were normalized to the right paw, intact hemisphere, usage and illustrated 
no significant changes between the DNSP-11 and vehicle treatment groups 
(F(1,22) = 2.32, p = 0.142) (Figure 5.2). 
DA Neurochemistry in Neuroprotection Studies 
Seven weeks after DNSP-11 or vehicle treatment and 6-OHDA delivery, 
animals were euthanized and tissues were dissected from the striatum and SN. 
Neurochemical analysis by HPLC-EC determined the neurochemical content of 
the tissue and no significant statistical differences were observed in DA, DOPAC, 
or HVA content in the SN or striatum (Table 5.2). 
The turnover ratio was calculated to provide insight into metabolic aspects 
of DA (Figure 5.3). The only area to exhibit significant increases in DA 
metabolism was the area DNSP-11 was delivered, the right striatum (t(13) = 2.46, 
p = 0.019). DNSP-11 increased the turnover ratio in the right striatum from 2.373 
± 0.19 to 3.272 ± 0.26. All other areas of interest did not show any significant 
changes in the ratio of metabolites (Rt SN: (t(12) = 0.356, p = 0.729), Lft striatum: 
(t(12) = 0.752, p = 0.467), Lft SN: (t(12) = 0.986, p = 0.344). 
Neuroprotection Study TH Immunohistochemistry  
Qualitative visual analysis of TH staining within the SN and striatum 
revealed no observable differences between the treatment groups (Figure 5.4). 
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Figure 5.1 Amphetamine-Induced Rotation Behavior beginning 3 
weeks after Treatment with DNSP-11 or Vehicle and 6-OHDA 
Total rotation behavior collected weekly beginning 3 weeks after neurotoxin / 
treatment delivery and assessed for a total of 4 weeks. Data were analyzed by a 
two-way ANOVA for repeated measures with Bonferroni’s post-hoc tests 
comparing differences between each group (F(1,22) = 0.18, p = 0.676). No 
significant differences were observed between DNSP-11 and vehicle treatment 
groups (n=12). 
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Figure 5.2 Percentage of Right Paw Placement before and after 
Striatal Treatment of DNSP-11 or Vehicle and 6-OHDA 
Paw placement was assessed once before treatment and 6-OHDA delivery and 
twice afterward. Data are shown as a percentage of the intact hemisphere’s paw 
usage allowing for changes due to habituation and reduction in activity. Analysis 
of the data were performed by a two-way ANOVA for repeated measures (F(1,22) 
= 2.32, p = 0.142) with Bonferroni’s post-hoc tests comparing DNSP-11 to 
vehicle treatment groups. No significant differences were seen between 
treatment groups (n=12). 
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Table 5.2 Neurochemical Content of the striatum and SN, 7 weeks 
after striatum Treatment of DNSP-11 or Vehicle and 6-OHDA Delivery 
Tissue 
Sample 
Neurochemical  
Analyte 
Vehicle Group 
Neurochemical 
Content (ng/g) 
DNSP-11 Group 
Neurochemical 
Content (ng/g) 
t and p values 
for Student’s t 
test 
Lesioned 
SN 
DA 170.4 ± 34.1 195.8 ± 39.1 t(17) = 0.484, p = 0.634 
DOPAC 69.38 ± 17.21 62.13 ± 12.17 t(17) = 0.349, p = 0.731 
HVA 164.3 ± 31.25 333.5 ± 71.12 t(17) = 0.052, p = 2.095 
Lesioned 
striatum 
DA 514.4 ± 103.7 486.4 ± 77.64 t(17)= 0.220, p = 0.827 
DOPAC 984.1 ± 228.4 1296 ± 247.3 t(17)= 0.369, p = 0.910 
HVA 230.2 ± 34.17 247.9 ± 27.43 t(17)= 0.409, p = 0.685 
Intact SN 
DA 469.4 ± 38.22 481.5  ± 85.93 t(17) = 0.123, p = 0.903 
DOPAC 160.7 ± 16.73 164.7 ± 22.71 t(17)= 0.889, p = 0.142 
HVA 156.1 ± 31.61 191.2 ± 34.21 t(17)= 0.747, p = 0.465 
Intact 
striatum 
DA 1879 ± 186.7 2560 ± 334.2 t(17)= 1.673, p = 0.103 
DOPAC 1656 ± 213.4 2063 ± 235.4 t(17)= 1.257, p = 0.216 
HVA 316.1 ± 39.75 349.9 ± 35.08 t(17)= 0.640, p = 0.526 
DA related neurochemical content in the striatum and SN of both the intact and 
lesioned hemispheres 7 weeks after DNSP-11 or vehicle treatment and 6-OHDA 
Delivery. No significant changes in DA related tissue neurochemistry after 
treatment were detected comparing DNSP-11 and vehicle treatment groups with 
an unpaired two-way Student’s t-tests. The t and p values for each t-test can be 
found in the table above along with mean ± SEM values for the neurochemical 
content (n=10). 
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Figure 5.3 Ratio of DA metabolism 7 weeks after DNSP-11 or vehicle 
treatment and 6-OHDA delivery 
Turnover ratios comparing DNSP-11 and vehicle treatment in the striatum and 
SN of both hemispheres. All data sets were analyzed with a two-tailed Student’s 
t-test determining significant increases in DA metabolism by DNAP-11 treatment 
within the Rt striatum. Rt SN: (t(17) = 1.45, p = 0.17), Rt striatum: (t(17) = 2.46, p = 
0.019), Lft SN: (t(17) = 1.47, p =  0.16), Lft striatum: (t(17) = 0.256, p = 0.80), * p < 
0.05. Data: Mean ± SEM, n = 10. 
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Figure 5.4 TH Immunohistochemistry in the SN and striatum 7 weeks 
after treatment with DNSP-11 or vehicle and 6-OHDA 
TH positive staining after DNSP-11 or vehicle treatment showed a lack of 
qualitative differences between the vehicle and DNSP-11 treatment groups in 
either striatum or SN brain regions 7 weeks after treatment delivery. Slices A, B, 
D, and E were observed under 10 x magnification, while C and F were visualized 
at 50 x magnification (n=2). 
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Severe MFB Lesion in the F344 Rat  
6-OHDA was delivered to two points along the MFB and provided a 
severe lesion with a minimum 90% reduction in DA content in both the striatum 
and SN. When comparing the intact hemisphere to the lesioned hemisphere in 
vehicle treated animals, there was a reduction in striatum DA from 7601 ± 310.9 
to 60.85 ± 11.85 ng/g, a 99.2% reduction, and in the SN DA content decreased 
from 1637 ± 269.5 ng/g to 34.65 ± 6.44 ng/g  a reduction of 97.9% (Figure 5.5). 
Analysis of the DA reduction showed both the striatum (t(14) = 5.94, p < 0.0001) 
and SN (t(14) = 24.23, p < 0.0001) had significant loss of DA content. 
Apomorphine Induced Rotational Behavior 
Apomorphine was utilized to induce a turning behavior that has been 
correlated with DA content within the SN and striatum (Hudson et al., 1993). 
Apomorphine-induced rotational behavior was used as a screening tool to 
separate animals into two groups, vehicle and DNSP-11 treatment, with equal 
drug induced rotation behavior. Before treatment (Pre), the DNSP-11 group had 
95.0 ± 7.8% of the number of vehicle group rotations. One week after infusion 
treatment, apomorphine-induced rotation behavior in the DNSP-11 treatment 
group had significantly decreased to 56.9 ± 7.3% of the vehicle group (Figure 
5.6). The reduction in rotational behavior was seen at all four time points after 
DNSP-11 treatment (Week 2: 50.63 ± 10.48% Week 3: 61.43 ± 6.88% Week 4: 
61.08 ± 6.38%, F(4,39) = 4.807, p= 0.0005). 
6-OHDA Tissue Neurochemistry  
The level of apomorphine-induced rotation behavior has been shown to 
inversely correlate with DA content, but to validate the hypothesized changes in 
neurochemistry, HPLC-EC methods were used to measure the neurochemical 
content of tissue samples from the SN and striatum of all animals 5 weeks after 
treatment. Tissue DA levels in the lesioned SN of the vehicle treatment group 
was 34.65 ± 6.44 ng/g and the DNSP-11 treatment group was significantly 
increased to 59.10 ± 7.31 ng/g (t(13)= 2.521, p=0.0265) (Table 5.3).  
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Figure 5.5 6-OHDA-induced striatal and SN reductions in DA content 
Comparison of the DA content in the striatum and SN of vehicle treated animals 
demonstrating the effects of the 6-OHDA MFB lesion. A highly significant 
reduction of DA content was observed in both the SN (t(14) = 5.94, p < 0.0001) 
and striatum (t(14) = 24.23, p < 0.0001) when analyzed by a two-tailed Student’s t-
test. *** p < 0.0001 Intact vs. lesion. Data: Mean ± SEM, n = 8. 
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Figure 5.6 Reduction in Apomorphine Induced Rotation Behavior 
after DNSP-11 Treatment 
Percentage of vehicle rotational behavior showing significant reductions in 
apomorphine-induced rotation behavior by DNSP-11 at all 4 time points after 
infusion treatment. Data was analyzed by a One-way ANOVA for repeated 
measures (F(4,39) = 4.807, p= 0.0005) with Bonferroni’s post-hoc tests to compare 
all weeks rotation behavior with the prescreen rotation behavior * p < 0.05, * p < 
0.01 (n=8). 
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Table 5.3 Neurochemical content of the SN and striatum 5 weeks 
after infusion treatment with DNSP-11 or Vehicle 
Tissue 
Sample 
Neurochemical  
Analyte 
Vehicle Group 
Neurochemical 
Content (ng/g) 
DNSP-11 
Group 
Neurochemical 
Content (ng/g) 
t and p values 
for Student’s t 
test 
Lesioned 
SN 
DA 34.65 ± 6.44 59.10 ± 7.31* t(13)= 2.521, p=0.0265 
DOPAC 7.10 ± 1.40 16.48 ± 4.01* t(13)= 2.330, p=0.0364 
HVA 40.66 ± 17.74 42.41 ± 11.52 t(13) =0.083, p = 0.935 
Lesioned 
striatum 
DA 60.85 ± 11.58 61.37 ± 10.21 t(14)= 0.034, p=0.974 
DOPAC 33.99 ± 8.43 45.01 ± 9.52 t(14)= 0.868, p=0.400 
HVA 20.80 ± 6.33 16.75 ± 2.13 t(14)= 0.606, p = 0.554 
Intact 
SN 
DA 1637 ± 269.5 2137 ± 354.1 t(13) = 1.124, p =0.280 
DOPAC 355.7 ± 90.50 276.8 ± 50.88 t(13) = 0.760, p = 0.460 
HVA 116.2 ± 21.27 136.8 ± 35.01 t(13) = 0.502, p = 0.624 
Intact 
striatum 
DA 7601 ± 310.9 9056 ± 707.7 t(14)= 0.081, p= 1.883 
DOPAC 1716 ± 145.6 2335 ± 165.9* t(14)= 2.806, p= 0.0140 
HVA 686.2 ± 55.39 738.3 ± 70.05 t(14)= 0.584, p= 0.569 
Striatum and SN DA, DOPAC, and HVA content from tissue collected 5 weeks 
after treatment with DNSP-11 or vehicle. All neurochemical content in DNSP-11 
treated animals was analyzed relative to the neurochemical content of the vehicle 
treated animals using a two-tailed Student’s t-test *p < 0.05. Data: Mean ± SEM, 
n = 8. 
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DOPAC levels in the vehicle treatment group were 7.10 ± 1.40 ng/g while 
DOPAC levels in the DNSP-11 treatment group were significantly increased to 
16.5 ± 4.0 ng/g (t(13)= 2.33, p=0.0364) (Table 5.3). No significant changes in HVA 
were detected in the lesioned SN (Table 5.3). The striatum of the lesioned 
hemisphere demonstrated no DA related neurochemical changes. The intact 
striatum, contralateral from the SN in which DNSP-11 was administered, showed 
significant changes in DOPAC between the vehicle treatment group with a level 
of 1716 ± 145.6 ng/g and the DNSP-11 treatment group with a significantly 
increased level of 2335 ± 165.9 (t(14)= 2.806, p=0.0140). No significant changes 
in neurochemistry were detected in the intact SN.  
DA metabolism in the SN and striatum was calculated by dividing the total 
DA metabolite (DOPAC + HVA) content of an area by the DA content. There 
were no differences between turnover or metabolism ratios between the DNSP-
11 and vehicle treated groups (Figure 5.7).  
Neurorestoration Study TH Immunohistochemistry 
A qualitative analysis of TH staining in each treatment group revealed 
potential increases in fiber density within the striatum and possible increases in 
the number of cell bodies and fiber density within the SN of DNSP-11 treated 
animals (Figure 5.8). Only two animals from each group were used for TH 
immunohistochemistry but consistent increases in TH positive neurons were 
observed in the DNSP-11 treatment group. However, the magnitude of the 
increases in TH immunohistochemistry varied between DNSP-11 treated 
animals. 
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Figure 5.7 DA Metabolism in a 6-OHDA Lesioned Rat 5 Weeks after 
SN Infusion Treatment 
The ratio of tissue DA metabolites to tissue DA 5 weeks after infusion treatment 
was not significantly different in any brain region. Data from each brain region 
was analyzed using a two-tailed Student’s t-test; Rt striatum: (t(12) = 0.814 , p = 
0.432), Rt SN: (t(12) = 0.356 , p = 0.729), Lft striatum: (t(12) = 0.752 , p = 0.467), Lft 
SN: (t(12) = 0.986 , p = 0.344). Data: Mean ± SEM, n = 8. 
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Figure 5.8 TH Immunohistochemistry 5 weeks after DNSP-11 
Treatment 
TH Immunohistochemistry was investigated in two animals per treatment group 5 
weeks after infusion delivery. Photographs A – C and G – I were taken from the 
two animals treated with citrate buffer vehicle, while D – F and J – L where taken 
from the two animals treated with DNSP-11. TH staining showed possible 
increases in the cell body number and enhanced dendritic arborization within the 
SN. Continued on the next page. 
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Figure 5.8 Continued 
Corresponding increases in TH positive fiber density were observed in the 
striatum. The DNSP-11 animals do not reveal the same magnitude of TH staining 
both do demonstrate restoration of TH expressing neurons. Further investigation 
and replication of this study will be necessary to determine typical TH staining 
after DNSP-11 treatment. Photographs A, B, D, E, G, H, J and K were all 
visualized under 10 x magnification, while C, F, I and L were observed under 50 
x magnification (n=2). 
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Discussion 
In an effort to determine DNSP-11’s ability to protect dopaminergic 
neurons from neurotoxin-induced cell loss, DNSP-11 was delivered before 
neurotoxin treatment. No significant alterations in behavior were observed in the 
DNSP-11 pretreatment group when compared to vehicle in either rotational 
behavior or paw placement. The lack of behavioral changes would suggest 
limited neurochemical differences between the DNSP-11 and vehicle treatment 
groups providing evidence of a similar dopaminergic loss in both treatment 
groups. Therefore, minimal to no protection was provided by DNSP-11 treatment 
and this assumption was validated using the neurochemical content of the tissue. 
The neurochemical content showed no significant increases in DA, DOPAC, or 
HVA between treatment groups providing further evidence for a lack of significant 
neuroprotective effects by DNSP-11.  
When the tissue neurochemical analysis was examined, reductions in the 
DA content in the striatum were not paralleled by DA metabolite reductions of the 
same magnitude. DA metabolism was increased, which was demonstrated 
through the significant increase in turnover ratio implying increases in DA 
signaling or production possibly within the weeks before the tissue collection 
(Hudson et al., 1995). The possibility remains that there was an increase in DA 
synthesis before tissue dissection and the observed effects on metabolism are all 
that remains 7 weeks after DNSP-11 treatment. But, that would also imply the 
changes in DA synthesis were not robust enough to elicit behavioral changes in 
the DNSP-11 treated animals. The lack of a neurochemical effect could also be 
related to the area of administration, since all previous studies delivered DNSP-
11 to the SN. The retrograde transport of DNSP-11 has not been established, 
and therefore if the target of action for DNSP-11 is only located in the SN, then 
DNSP-11 may not reach its target. From the results of the neuroprotection study, 
it was hypothesized that DNSP-11 is minimally transported to the SN and DSNP-
11 treatment provides nominal lasting effects on DA neurochemistry. Minimal 
delivery of DNSP-11 to its site of action would explain the lack of observed 
effects on TH staining or behavior and the mild effect on DA metabolism. 
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To determine DNSP-11’s ability to restore a damaged dopaminergic 
system, DNSP-11 or vehicle was infused into the SN of F344 rats exhibiting 
severe and stable dopaminergic cell loss (>95 %). DNSP-11 improved 
dopaminergic function within the severely lesioned nigrostriatal pathway; 
decreasing apomorphine induced rotation behavior and increasing tissue content 
of both DA and DOPAC. TH immunohistochemistry showed possible increases in 
the number of TH+ cell bodies and fiber density in the SN and increases in fiber 
density in the striatum.  
The reduction of rotational behavior in the severely lesioned rat by DNSP-
11 treatment is most likely directly related to increased synthesis and release of 
DA within the SN (Robertson and Robertson, 1988, 1989). Increased levels of 
DA would decrease the post-synaptic receptor supersensitivity and reduce the 
activation related to the DA receptor agonist, apomorphine (Kostrzewa, 1995; 
Kostrzewa et al., 2008). The behavioral manifestation, though drug induced, was 
the first instance behavioral modification related to DNSP-11 induced 
neurochemical changes was observed.  
Tissue neurochemical analyses were performed to confirm the presumed 
neurochemical changes and demonstrated significant increases in DA and 
DOPAC in the SN ipsilateral to the lesion. The increase in DA and DOPAC may 
be related to increases in DA synthesis either through the restoration of damaged 
dopaminergic neurons or enhancement of the remaining functional dopamine 
neurons. TH staining could indicate improvements in the number of damaged 
dopaminergic neurons because of the increased density in TH positive neurons, 
but this does not preclude the possibility of simultaneous enhancement of 
function in surviving neurons. Baseline neurochemical data from chapter 3 
(Figure 3.7) showed an increase in baseline extracellular dopamine, which would 
be best explained by the enhancement of DA release. Therefore, DNSP-11 was 
able to improve and/or enhance the function of the nigrostriatal pathway five 
weeks after a 95 % loss of function.  
In the lesioned animals, the intact hemisphere had altered DA 
neurochemistry after DNSP-11 treatment with increases in DOPAC tissue 
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content. The possibility of DNSP-11 reaching the contralateral hemisphere 
through diffusion is unlikely because it is removed from the extracellular space 
within 2 hrs of delivery (Bradley et al., 2009 (Submitted)).It is more likely that 
there is signaling between the two hemispheres causing compensatory changes 
after DNSP-11 related increases in function.  
Results from studies of GDNF have previously demonstrated 
neuroprotective and neurorestorative effects against similar models of neurotoxin 
induced cell death. DNSP-11’s restorative effects on the severely damaged 
dopaminergic system parallel GDNF’s effects in all measured parameters 
including TH staining, neurochemistry, and rotation behavior (Hoffer et al., 1994; 
Bowenkamp et al., 1995). GDNF showed a similar ability to affect the 
contralateral hemisphere neurochemistry in both non-human primate and rodent 
models (Hoffer et al., 1994; Slevin et al., 2005; Stanford et al., 2007). 
Neuroprotective studies demonstrate a drastic difference between GDNF 
and DNSP-11. GDNF delivered to the striatum was able to protect against 
dopamine cell loss induced by 6-OHDA in both the SN and striatum (Kirik et al., 
2000). Significant increases in rotational behavior and forepaw use were 
observed as well as enhanced TH positive fiber density. Effects on TH positive 
fiber staining or behavior demonstrated by GDNF were not mimicked by DNSP-
11. This provides further evidence of drastically different mechanisms between 
the two molecules possibly related to DNSP-11’s site of action and lack of 
retrograde transport. 
Chapter Summary 
DNSP-11 did not provide neuroprotection when delivered to the striatum 6 
hours before 6-OHDA. Minimal neurochemical effects were demonstrated by 
DNSP-11 on DA metabolism, but no neuroprotective effects were observed in TH 
staining, behavior, or tissue neurochemical. Minimal effects by DNSP-11 in the 
neuroprotection model could be due to the striatal delivery, a lack of DNSP-11 
retrograde transport, and localization of DNSP-11’s site of action to the SN. The 
lack of a neuroprotective effect could be attributed to the molecular properties of 
the molecule and mechanism of action. In a rat model of severe nigrostriatal 
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dopaminergic cell loss, DNSP-11 was able to restore dopaminergic function, 
modulate behavior, and possibly increase TH fiber density in both the striatum 
and SN (Table 5.4). DNSP-11 demonstrated potential as a therapeutic agent to 
restore and/or enhance the function of a severely damaged dopaminergic 
system. The restorative or enhancing actions of DNSP-11 support the molecule’s 
therapeutic potential and warrant continued study in models of dopaminergic 
function. 
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Table 5.4 Comparison of the Effects of DNSP-11 and GDNF in the 
Severe 6-OHDA Lesion 
 
Comparison of the effects of DNSP-11 and previous work with GDNF in the 
severe 6-OHDA-lesioned rat showed similar alterations in the nigrostriatal 
dopaminergic system. Both GDNF and DNSP-11 reduced apomorphine-induced 
rotations, increased DA and DOPAC content in the SN, and enhanced TH+ 
neuron density.  
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Chapter Six: Major Conclusions and Future Directions 
In all rat models studied in this dissertation DNSP-11 treatment modified 
DA function. In the young adult F344 rat, DNSP-11 enhanced dopaminergic 
function (Chapter 3); in the 24 month old F344 rat, DNSP-11 reduced basal and 
releasable DA (Chapter 4); in severely lesioned F344 rat, DNSP-11 improved 
dopaminergic function (Chapter 5); and pretreatment with DNSP-11 in the F344 
rat before neurotoxic insult modified DA metabolism (Table 6.1). Thus, DNSP-11 
enhances dopaminergic function in the F344 rat.  
Mechanisms of DNSP-11 Activity 
The differential activity of DNSP-11 relative to the established effects of 
GDNF is evidence that peptides cleaved from the prodomain may have 
alternative signaling relative to their parent molecules. Bradley et al. (Submitted 
2009) provided evidence of DNSP-11 signaling through a pathway other than the 
GFRα1 receptor, the known signaling pathway for GDNF. According to Bradley et 
al. (Submitted 2009), DNSP-11 directly binds the glycolytic protein 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and could be the origin of 
DNSP-11’s function. GAPDH has a multitude of functions beyond glycolysis such 
as RNA export, DNA maintenance and repair, exocytotic membrane fusion, and 
cytoskeletal organization (Sirover, 1999, 2005). A recently identified function of 
GAPDH is the initiation of apoptotic cascades by nuclear translocation (Berry and 
Boulton, 2000). The induction of apoptosis and malfunction of GAPDH has been 
implicated in the energy dysfunction and progressive cell loss associated with 
aging and neurodegenerative disease (Mazzola and Sirover, 2002, 2003). 
Modulation of GAPDH by DNSP-11 would potentially modulate 
metabolism and apoptosis possibly enhancing the function and increasing 
survival of dopaminergic neurons. Deprenyl, also known as selegiline, a selective 
MAO B inhibitor, has anti-apoptotic functions through GAPDH. GAPDH binding 
selectively decreases synthesis of pro-apoptotic proteins and increases synthesis 
of anti-apoptotic proteins (Tatton et al., 1995; Tatton et al., 2003; Hara et al., 
2006). DNSP-11 could have similar actions to deprenyl modifying apoptosis,  
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Table 6.1 Summary of DNSP-11 Related Effects on DA in Rat Model 
Systems  
 Modulation of DA  
F344 Rat Model Synthesis Metabolism Release Fiber/Cell Body Density 
Normal 
(3-6 Month) + + + +/? 
Aged 
(24-26 Month) _ _ + _ 
Severe MFB Lesion 
(Neurorestoration) + + _ +/? 
Striatal Lesion 
(Neuroprotection) _ + _ _ 
A table summarizing the effects of DNSP-11 on DA function in each of the 
previous chapters using the specified rat models. + Positive, – Negative, ? 
Inconclusive 
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energy utilization, and MAO function (Berry, 2004). DNSP-11 binds GAPDH 
similarly to deprenyl and has parallel neurochemical effects. The potential anti-
apoptotic function through GAPDH binding could explain the restorative effects 
demonstrated by DNSP-11 (Lamensdorf et al., 1996). Therefore, interaction with 
both MAO and GAPDH by DNSP-11 could explain the similarities to deprenyl’s 
neurochemical and anti-apoptotic actions.  
DNSP-11 shares functional similarities with GDNF, but Bradley et al. 
(Submitted 2009) provided evidence of a divergence in mechanism because 
DNSP-11 does not bind to the GFRα1 receptor. Induction of GDNF production by 
DNSP-11 would potentially explain many of the neurochemical effects observed 
within this dissertation. The induction of GDNF production and subsequent 
trophic actions could explain the enhanced neurochemical function and 
neurorestoration observed in the rat but would not explain the acute effects of 
DNSP-11. The function of DNSP-11 and GDNF were investigated by Bradley et 
al. (Submitted 2009) by comparing DNSP-11 and GDNF as neuroprotective 
agents against mitochondrial toxins. DNSP-11 showed neuroprotective effects 
and blocked the release of cytochrome C, while GDNF was unable to provide 
any neuroprotective effects against mitochondrial induced apoptosis. DNSP-11 
and GDNF differ in their ability to bind GFRα1 and in their mechanisms of 
mitochondrial neuroprotection showing differences in function. Difference in 
mechanism and function between GDNF and DNSP-11 do not preclude the 
possibility for DNSP-11 to modulate GDNF translation. Therefore, future studies 
will be necessary to determine if DNSP-11 effects the translation of its parent 
molecule, GDNF.  
DNSP-11 may induce GDNF translation, but it is also possible that GDNF 
and DNSP-11’s distinct signaling pathways could converge on similar targets 
such as the ERK/MAPK pathway GDNF signals through (Sariola and Saarma, 
2003). A convergence of signaling pathways could provide similarities of function, 
while maintaining distinct differences. As noted earlier, DNSP-11 interacts with 
GAPDH and could potentially alter neurochemical function through inhibition of 
MAO or convergence with a GDNF related signaling pathway. To allow the 
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development of molecules targeting specific aspects of DNSP-11 signaling, the 
potential signaling pathways for DNSP-11 activity need to be investigated.  
The Significance of the DNSPs 
Generally, the prodomains of trophic factors have been theorized to only 
be involved in protein folding and synthesis with no distinct function after 
cleavage (Ibanez, 2002). Prodomains of the trophic molecules BDNF and NGF 
modulate signaling activity but primarily in conjunction with the mature protein 
(Lee et al., 2001; Chen et al., 2005; Teng et al., 2005b). The modulation of 
dopaminergic function by DNSP-11 is evidence for a potential paradigm shift in 
the activity of peptides cleaved from the prodomain of trophic factors. Peptides 
from the prodomains of other neurotrophic factors need to be investigated 
because of the potential discovery of other peptides with signaling activity. 
The primary goal of this dissertation was to determine if the DNSPs 
provide any physiological effects on the dopaminergic system, and if so 
determine the potential therapeutic value of those effects. Alteration of 
dopaminergic function assessed through neurochemical analysis was the primary 
endpoint of interest in all studies. One of the DNSPs, DNSP-11, has 
demonstrated positive physiological effects on neurochemical function within the 
nigrostriatal dopaminergic system. Effects on dopaminergic function have been 
seen in multiple model systems of dopaminergic dysfunction and the effects 
show the potential DNSP-11 has for providing the basis for future molecules 
targeting the enhancement or restoration of dopaminergic function. An eleven 
amino acid peptide providing robust modulation of the dopaminergic system is 
completely novel. More importantly, these studies provide the foundation for 
future work investigating mechanistic and therapeutic aspects of DNSP-11.  
Much of the work discussed in this dissertation was compared to previous 
work with GDNF because of the therapeutic potential demonstrated by GDNF in 
the laboratory. GDNF demonstrated the most robust and lasting trophic effects 
on dopaminergic neurons of any known trophic factor, but failed in the clinic 
because of aspects related to delivery and toxicity. Results obtained during the 
completion of this dissertation could potentially be used in the development of a 
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molecule that maintains the trophic function of GDNF but lack some of the 
detrimental aspects. DNSP-11 has demonstrated the potential to have trophic 
actions like GDNF, but DNSP-11’s size and molecular properties could reduce 
the negative aspects associated with GDNF. DNSP-11 is easily synthesized and 
can be readily modified to modulate function. Continued study of DNSP-11 can 
provide the necessary basis for a molecule that is non-toxic, easily administered, 
and restores dopaminergic function.   
Future Work 
In the studies within this dissertation, neurochemical measures were 
always granted precedence over all other endpoints because dopaminergic 
function was the primary endpoint of interest. Therefore, the TH 
immunohistochemical data within this dissertation is not definitive but merely 
supporting data for the neurochemical studies. Studies within this dissertation 
have established positive neurochemical effects from DNSP-11 treatment but it 
will be necessary in the future for TH immunohistochemistry to be the primary 
endpoint when studying DNSP-11. Studies definitively identifying TH positive 
neurons after DNSP-11 treatment will distinguish functional enhancement and 
restoration; thus providing more insight into the actions of DNSP-11.  
To establish the value of DNSP-11 as a therapeutic, the areas GDNF was 
deficient in need to be explored such as the route of administration and toxicity. 
The small size of DNSP-11 relative to other trophic factors provides the potential 
for a molecule that could be delivered through intranasal or intravenous delivery 
making it a much more widely used and safe intervention. Also, the size could 
allow for larger dispersion upon delivery thus permitting DNSP-11 to affect 
dopaminergic function in an increased neuronal population. Exploration of DNSP-
11’s toxicity will also be necessary in the future to continue the progression 
towards use as a therapeutic. 
The rat model systems used in this dissertation allowed the exploration 
and discovery of DNSP-11’s effects but have not always been effective 
predictors of function in humans. Testing DNSP-11’s function in animals more 
closely related to humans, such as non-human primates (NHP), will be 
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necessary to translate DNSP-11 into a therapeutic. The larger size and 
complexity of the NHP brain will allow aspects of distribution and delivery to be 
more thoroughly addressed. Future studies of DNSP-11 in NHP models of 
dopaminergic dysfunction will determine if DNSP-11 can modulate and restore 
dopaminergic function without adverse effects. Studying DNSP-11 in the NHP 
will provide insight into DNSP-11’s action within the primate brain and its ability to 
modulate dopaminergic function. 
Final Thoughts 
The study of DNSP-11’s potential as a therapeutic has the goal of 
developing a therapeutic for diseases related to dopaminergic dysfunction such 
as PD. The ambition of the author and the many collaborators studying DNSP-11 
is the development of a treatment for PD that would allow the restoration and 
enhancement of dopaminergic function. Restoration of dopaminergic function 
could replace or increase the effectiveness of the chemical replacement 
therapies currently available. DNSP-11 has the potential to restore dopaminergic 
function and in turn restore the quality of life to individuals suffering from PD but 
reaching that potential will require continued exploration and understanding. 
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Appendix: Isoflurane Affects Evoked Glutamate Release 
Isoflurane anesthesia was associated in the modulation of 
neurotransmitter function in Chapter 4. DA neurochemical release was potentially 
altered by anesthesia through interactions with the DA autoreceptor (Tsukada et 
al., 1999). To further explore isoflurane-mediated effects on neurochemical 
release, another prominent striatal neurotransmitter was examined, glutamate. 
Previous work in our lab has focused on anesthetic interactions with 
neurotransmitters in an effort to design experiments and interpret data. Urethane, 
an injectable anesthetic, has been extensively used in anesthetized recording 
preparations but recently was implicated in reducing the basal extracellular 
concentrations of glutamate relative to the awake animal and the isoflurane 
anesthetized animal (Rutherford et al., 2007; Stephens, 2009). Isoflurane was 
considered as the primary anesthetic to replace urethane in anesthetized 
preparations for neurochemical recordings. Therefore, isoflurane’s effects on 
neurochemistry needed to be investigated because it has been implicated in 
neurochemical modulation in vitro. Isoflurane has been associated with increases 
in the basal extracellular concentration of glutamate in brain slices (Eilers and 
Bickler, 1996). Also, in brain slices, isoflurane reduces excitatory postsynaptic 
potentials and reduces the glutamate content of vesicles (Berg-Johnsen and 
Langmoen, 1992). Isoflurane’s effects on glutamatergic function have been 
principally observed in slice and primary cell culture preparations. In vivo 
recording techniques allow for the measurement of stimulus-evoked glutamate 
release and basal glutamate concentrations in an isoflurane-anesthetized rat that 
maintains all of the glutamatergic inputs. The intact rat can provide a better 
understanding of the effects of isoflurane on glutamate release and, therefore, 
will allow insight into future study designs and interpretation of previous results.  
Measurement of glutamate in isoflurane (2 - 3%) anesthetized rats used a 
ceramic microelectrode array (MEA) with four platinum recording sites. All four 
recording sites were electroplated with m-phenylenediamine, creating a size 
exclusion layer (A.1). The size exclusion layer allows only small molecules, such 
as hydrogen peroxide, to reach the platinum recording sites. Two of the recording 
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sites were also coated with glutamate oxidase (GluOx), which reacted with 
glutamate to produce hydrogen peroxide and α-ketoglutarate while the other two 
sites did not have a GluOx coating (Burmeister and Gerhardt, 2003). The 
hydrogen peroxide molecule acts as a reporter molecule for glutamate and is 
oxidized on the platinum recording sites by applying a constant potential of +0.7V 
versus an Ag Ag/Cl reference electrode. The hydrogen peroxide molecule 
releases two electrons that are measured as current and subsequently digitized 
and amplified by the Fast 16 Mark II Electrochemical Recording System 
(Quanteon, Nicholasville, KY). Therefore, the GluOx-coated sites measure 
glutamate release while the other two sites only measure background current. 
The difference between the two pairs provides a noise-free, specific glutamate 
signal. MEAs were calibrated before the experiment as in (Burmeister et al., 
2002; Day et al., 2006). The described electrochemical recording technique was 
used to measure striatal glutamate basal concentrations and K+ evoked 
concentrations. The isotonic 70 mM K+ solution was delivered by a pipette affixed 
to the recording electrode. 
Glutamate release under urethane anesthesia was reproducible every 1-2 
minutes and agreed with previous results (Burmeister et al., 2002). Glutamate 
release peaks with amplitude of about 30 μM were observed when 100 nL of 70 
mM K+ was applied while baseline concentrations were below 1 μM (Figure A.2). 
Meanwhile, glutamate release under isoflurane did not produce consistent 
glutamate signals with a drastic reduction in glutamate release after the initial 
event. The initial evoked glutamate release event under isoflurane was also 
decreased relative to stimulated releases under urethane. Basal concentrations 
of glutamate were elevated under isoflurane relative to the concentration 
observed using urethane (Figure A.3). Additional time (~10 minutes) between 
evoked releases did not allow recovery of the glutamate signal, and increased K+ 
delivery up to 300 nL did not return evoked glutamate signals to levels 
corresponding to the initial release.  
The initial decline in evoked glutamate release could be related to a 
decrease in the excitability of glutamatergic neurons in isoflurane-anesthetized 
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animals. A reduction in the excitability of glutamatergic neurons could be caused 
by membrane hyperpolarization making fewer neurons responsive to stimulation 
with K+. The decline in excitatory post-synaptic potentials demonstrated by 
(Maclver et al., 1996; Larsen and Langmoen, 1998) is evidence of the potential 
modulation of presynaptic glutamate release. Previous studies showed evidence 
of a modulation of glutamate packaging under isoflurane, which could cause the 
observed lack of reproducible glutamate release (Berg-Johnsen and Langmoen, 
1992).  
Another component of glutamate regulation is the glutamate transporter, 
which is located on glial cells and is responsible for the removal of glutamate 
from the synapse. Isoflurane has demonstrated effects on glutamate transporters 
and the increased levels of basal glutamate could be related to a reduction in the 
function of the glutamate transporters (Do et al., 2002). All glutamatergic 
alterations could be the result of direct effects of isoflurane on components of 
glutamatergic signaling, but they could also be related to the activation of the 
group II metabotropic glutamate receptors (Harrison et al., 2008; Raiteri, 2008). 
Group II metabotropic glutamate receptors are presynaptic autoreceptors that 
negatively regulate glutamate signaling. Increased activation of the Group II 
metabotropic glutamate receptors by isoflurane could reduce the evoked 
glutamate signals similarly to the changes seen in release and basal 
concentrations (Spooren et al., 2003). 
Glutamate release and basal concentrations under urethane and 
isoflurane depict glutamate function in different manners. Both isoflurane and 
urethane anesthetics potentially alter releasable and basal glutamate 
concentrations. The differences in glutamate release under the two anesthetics 
highlight the necessity for investigating glutamate neurochemical signaling in 
awake animals to exclude the effects of anesthesia.  
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Figure A.1 Microelectrode Array 
A photograph of the tip of the microelectrode array used for recording glutamate. 
An exclusion layer of m-phenylenediamine is electroplated on all four sites and 
the bottom pair receives a coating of glutamate oxidase. The glutamate oxidase 
allows the microelectrode to be sensitive to glutamate, while the m-
phenylenediamine is size exclusion layer and increases selectivity for recording 
glutamate. 
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Figure A.2 Representative Trace of K+-evoked Glutamate Release 
under Urethane Anesthesia 
Representative traces of glutamate signals produced by K+-evoked release in the 
striatum of a urethane-anesthetized rat. The application of the K+ solution is 
marked by asterisks. Reproducible peaks were elicited by K+ with approximately 
1.5 minutes between release events. 
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Figure A.3 Representative Trace of K+-evoked Glutamate Release  
under Isoflurane Anesthesia 
Representative traces of glutamate signals produced by K+-evoked release in the 
striatum of an isoflurane-anesthetized rat. The applications of the K+ solutions 
are marked by asterisks. Increased basal glutamate concentrations, decreased 
initial response to K+ and a lack of reproducibility was observed while using the 
isoflurane anesthesia. 
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